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ABSTRACT
Proper protein quality control is essential for neuronal health and function, and 
there is substantial evidence for the dysregulation of proteostasis in a wide range 
of neuropathological conditions including the most common neurodegenerative 
diseases. Diminished function of the Ubiquitin Proteasome System, the major 
cellular pathway for the clearance of toxic or unwanted proteins, likely contributes 
to disease pathogenesis through numerous - and as yet, incompletely 
understood - mechanisms.  Here, I review recent studies exploring the role of the 
Ubiquitin Proteasome System in the most common neurodegenerative diseases.  
I then describe in-depth two research projects directed at further investigating 
one agent of the Ubiquitin Proteasome System whose expression is reduced in 
Alzheimer’s disease, the F-box Only Protein 2 (Fbxo2).  Using cell-based models 
and an Fbxo2 knockout mouse, I present evidence for a role for Fbxo2 in the 
turnover and processing of the Amyloid Precursor Protein, believed to be the 
major causative protein in Alzheimer’s disease. I then show that the loss of 
Fbxo2 results in greater expression and surface localization of NMDA receptor 
subunits, and enhances the formation of axo-dendritic shaft synapses.  Taken 
together, these studies support a central role for the Ubiquitin Proteasome 
System, and in particular Fbxo2, in the turnover and handling of key proteins in 
the pathogenesis of Alzheimer’s disease and the regulation of synaptic 
connections.
vi
Chapter One: Ubiquitin Pathways in Neurodegenerative Disease
ABSTRACT
Control of proper protein synthesis, function, and turnover is essential for the 
health of all cells. In neurons these demands take on the additional importance of 
supporting and regulating the highly dynamic connections between neurons that 
are necessary for cognitive function, learning, and memory.  To meet the 
demands of regulating multiple unique synaptic protein environments within a 
single neuron, while maintaining cell health, requires the highly regulated 
processes of ubiquitination and degradation of ubiquitinated proteins through the 
proteasome. In this review, we examine the effects of dysregulated ubiquitination 
and protein clearance on the handling of disease-associated proteins and 
neuronal health in the most common neurodegenerative diseases. 
INTRODUCTION
The unique demands placed on neurons by their exquisitely complicated and 
dynamic architecture have been appreciated by investigators for over a hundred 
years (1-3).  Recent studies place the number of neurons in the human brain at 
approximately 85 billion (4). With each neuron making upwards of 10 thousand 
synaptic connections, the estimated total number of synapses reaches toward 
8.5 hundred trillion (8.5 x 1014).  Astonishingly, plasticity can occur selectively at 
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particular subsets of synapses within a neuron, even down to the level of a single 
specified synapse (5). Failure to maintain these synaptic connections and their 
proper plasticity are hallmarks of a host of neurodegenerative diseases, and loss 
of synaptic connections correlates with diminished cognitive function even before 
neurons degenerate (6,7). With 2,788 unique proteins already identified as 
integral to the composition of each synapse (8), the management of unique 
protein environments requires sufficiently complex and modifiable systems of 
protein quality control.   The Ubiquitin Proteasome System (UPS), a set of 
interacting enzymes and associated proteins, is able to address these diverse 
proteostatic needs through the orchestrated activity of over 500 components 
working in versatile combinations to regulate protein-protein interactions and 
eliminate unwanted proteins.  As newly synthesized proteins form new structures 
and connections, the UPS works to insure that old proteins are degraded to 
make way and that the proper complement of building materials is available.  To 
achieve these functions, components of the UPS are recruited to dendritic spines  
in response to synaptic activity (9,10). Evidence continues to mount for the 
necessity of UPS involvement in the dynamic remodeling of synaptic structures 
following synaptic activity (11-17). This contribution to synaptic plasticity requires 
that the UPS function properly. For example, pharmacologic inhibition of the UPS 
reveals leads to a robust reduction in activity-dependent synaptic plasticity (12) 
and a dose-dependent loss of synaptic connections (18).  Robust loss of synaptic 
connections is evident in all of the major neurodegenerative disorders. Precisely 
how these synapses are lost remains unclear, but given its role in the 
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degradation of synaptic scaffolding proteins and cytoskeletal elements, 
ubiquitination is almost certainly involved. 
As important as the contribution of the UPS to maintaining the plasticity of 
synapses are its diverse roles in ensuring general cell health, including the 
elimination of misfolded or damaged proteins, mediation of receptor signaling 
pathways, response to DNA damage and oxidative stress, progression of the cell 
cycle, among other roles (19,20). UPS function is essential to cell health and 
survival in all cell types. Improper clearance of proteins is a causative or 
contributing factor in many neurodegenerative diseases, which are often 
characterized by the accumulation of aggregated proteins (21,22). Whether 
aggregation itself is the cause of toxicity or merely represents a strategy by which 
neurons sequester toxic proteins remains contested (23), but the failure of quality 
control pathways to eliminate these unwanted proteins is evident.  UPS 
dysfunction has been reported in the most common neurodegenerative diseases, 
including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic 
Lateral Sclerosis (ALS), and Huntington’s Disease (HD), as well as less common 
disorders and various animal models of protein aggregation (24-28). How the 
UPS becomes impaired in disease states is not always clear, as too little is 
known about how disease-related proteins are handled under normal conditions.  
Research into these areas has begun to reveal just how intricate and extensive 
the UPS is, and hopefully will uncover potential therapeutic interventions. 
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UBIQUITINATION AND THE UBIQUITIN PROTEASOME SYSTEM
Ubiquitin is a 76 amino acid (~8 kDa) protein expressed in all eukaryotic cells.  It 
is highly conserved throughout evolution; the amino acid sequence of human 
ubiquitin is identical to that of Aplysia (29) and nearly identical to that of yeast 
(30). Through the coordinated activity of multiple enzymes, ubiquitin is covalently 
added to substrate proteins through the formation of an iso-peptide bond 
between the C-terminal diglycine motif of ubiquitin and lysine residues on the 
target (Figure 1) (31).  This cascade begins with the ATP-dependent attachment 
of ubiquitin’s C-terminal glycine through a thio-ester bond to an active-site 
cysteine on an Ubiquitin Activating Enzyme (E1). This ubiquitin is then transferred 
to a Ubiquitin Conjugating Enzyme (E2) through a thio-ester bond. From there, 
the E2 enzyme will cooperate with a Ubiquitin Ligase (E3) to transfer the ubiquitin 
molecule to the target lysine on a substrate protein. This last step occurs 
differently depending on the type of E3 involved, but it is at this step that 
substrate specificity is believed to occur, with E3 ligases selecting substrates for 
ubiquitination.  However, this view has recently come under some scrutiny, as 
evidence emerges for a role for E2s in the process of substrate selection (32). 
E3s are typically grouped into three classes, with each defined by the specific 
protein domains it possesses.  These domain-based classes include: 1) Really 
Interesting New Gene (RING) finger-containing E3s, 2) Homologous to E6-AP 
(HECT) domain-containing E3s, and 3) E3s composed of multiple subunits.  
RING finger-containing E3s bring the E2 and the substrate protein into 
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sufficiently close proximity for the transfer of the ubiquitin to its target lysine (33). 
HECT-domain containing proteins possess an active-site cysteine to which the 
ubiquitin is first transferred from the E2 before being passed to the substrate 
protein (34). In contrast to these single-unit E3 ligases, multi-subunit ligases are 
composed of multiple adaptor proteins, cofactors, and scaffolding proteins that 
confer substrate specificity and facilitate ubiquitination (35).  The Skp1/Cul1/F-
box (SCF) protein complex and the Anaphase-promoting Complex (APC) are 
among the best studied of these multi-subunit E3s.  SCF complexes can include 
various combinations of scaffolding proteins called cullins, F-box proteins, and 
substrate adaptors (36). APC is less variable, containing Apc2, Apc11, and either 
Cdh1 or Cdc20 for substrate recognition (37). Further contributing to the 
complexity of these multi-subunit E3 ligases is the developmental and spatial 
restriction of their expression within cells (38). There are estimated to be at least 
500 different E3 ligases, with more continuing to be discovered (39).  Each E3 
can recognize multiple substrates; Fbxw1/β-TRCP1, for example, has upwards of 
40 documented substrates itself (40). 
This highly regulated process adds ubiquitin to target lysines on the substrate, 
but it can also add other ubiquitin molecules onto lysines of a ubiquitin already 
conjugated to a substrate.  By this process, ubiquitin chains of varying length and 
composition can be formed. The elongation of ubiquitin chains can occur at any 
of ubiquitin’s own seven lysines, resulting in the formation of different linkage 
types (41).  Although all possible linkage types are present in cells, their precise 
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functions remain only partially understood (42).  Chains formed through the 
addition of ubiquitin exclusively at lysine 48 (K48) have been recognized to signal 
protein degradation (43), whereas K63-linked ubiquitin chains seem to subserve 
diverse functions beyond protein degradation (44).  For example, K63-linked 
chains regulate NF-κB signaling not by promoting protein degradation but by 
influencing ubiquitin-dependent protein-protein interactions (45). Elsewhere, 
however, they been implicated in promoting the lysosomal degradation of the low 
density lipoprotein receptor (LDLR) (46) and the epidermal growth factor receptor 
(EGFR) (47). Both K48- and K63-linked chains have been observed to modify 
kinase activity in response to cellular stress, as have K11-linked chains (48,49).  
K11-linked chains are critical for cell-cycle regulation and cell division (50). Other 
linkages, including atypical, mixed-type linkages are less well studied, but have 
been implicated in similar processes within the cell (51,52). 
The functions thus far attributed to specific chain linkages represent only a 
fraction of the diverse roles ubiquitin is known to play in cellular processes (51), 
many of which do not depend on proteasome function (53).  Ubiquitination 
regulates DNA repair (54), protein localization and endocytosis (55-57), and 
protein-protein interactions (58,59).  Free, unanchored chains of ubiquitin 
molecules are also present in cells and can regulate numerous functions 
including kinase activation (60). The UPS has been also been implicated in the 
turnover of mRNA, although whether this regulation is direct or indirect remains 
unclear (61). Intriguingly, E3 ligases can themselves be targeted for 
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ubiquitination, offering an additional level of control for this important pathway 
(62,63).  The ubiquitination of E3 ligases can result either in their degradation or 
in the modification of their activity (64). 
Once a substrate is tagged for elimination through the addition of a ubiquitin 
chain, it must be targeted to the cell’s degradation machinery by chaperone 
proteins which recognize and bind to poly-ubiquitin chains. One such chaperone 
is Valosin-containing protein (VCP), which has been shown to physically interact 
with and shuttle poly-ubiquitinated substrates to the proteasome to facilitate their 
degradation (Figure 2) (65).  The proteasome contains a catalytic protein 
complex referred to as the 20S core (66), which is capped at each end by a 
regulatory protein complex (19S) (67,68). It is responsible for breaking down 
substrate proteins into small peptides (69,70).
The ubiquitination of substrate proteins is a reversible process. The removal of 
ubiquitin is carried out by De-ubiquitinating Enzymes (DUBs).  DUBs play two 
important roles, allowing for the editing of existing chains (71) and the removal of 
ubiquitin chains altogether from a substrate. As the presence of ubiquitin chains 
prevents substrates from entering the proteasome due to spatial restrictions, 
DUBs play an essential role in determining the rate of protein clearance in cells 
(31,72), and certain DUBs including USP14 are known to associate directly with 
the19S regulatory complex of the proteasome (73). 
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Numerous studies report proteasome dysfunction and the accumulation of 
ubiquitinated proteins in disease states. But it is important to consider that 
proteasomal degradation is only one of several potential outcomes of 
ubiquitination.  Indeed, there are numerous examples of dysregulated protein 
handling due to failures in ubiquitination that do not necessarily implicate the 
proteasome. Whether the effects of proteasomal failure reach upstream to impact 
the activity and efficacy of E1s, E2s, or E3s is not clear. Given that K48-linked 
chains are among the most common found in cells (74), it is conceivable that 
impaired proteolysis could deplete cellular pools of free ubiquitin and thereby 
induce further dysfunction. Accordingly, an imbalance in ubiquitination/
deubiquitination activities may result in improper chain formation, preventing the 
proteasome from recognizing and handling targeted substrates. To examine 
these two separate yet related phenomena, it will be helpful to distinguish 
whether dysfunction occurs in UPS per se or, more broadly in the Ubiquitin 
Signaling System (USS) which includes the labeling of proteins with ubiquitin for 
any number of intended outcomes beyond degradation. While impaired 
clearance characterizes UPS failure, it remains to be seen whether and how the 
other, non-proteasomal components of the USS contribute to disease processes.  
One example of this distinction is evident in the ubiquitin-mediated fate of 
Caspase proteins. 
Though the precise methods by which neurons degenerate in disease remain 
unclear, substantial evidence supports a role for proteases of the Caspase family. 
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For example, activated caspases are elevated in Alzheimer’s Disease (AD) 
patient tissue (75).  Upon activation, caspases can either activate other 
proteases (initiator caspases) or damage essential components of the cell and 
promote apoptosis (effector caspases). Sublethal amounts of caspase activation 
have been linked to synaptic dysfunction in an animal model of AD (76). 
Caspase-mediated effects can be inhibited both by the inactivation of caspase 
enzyme activity and by their targeted degradation through the proteasome.  The 
X-linked Inhibitor of Apoptosis Protein (XIAP) and its family member cIAP1 are 
RING-type E3 ligases that directly bind to and target caspases for degradation; 
XIAP is also able to inhibit the proteolytic activity of caspases (77,78).  The 
regulation of caspases by XIAP is limited, however, in oxidative stress conditions. 
Both acute and chronic inflammation, which are often associated with disease, 
elevate the levels of nitric oxide in neurons. This elevation can lead to the 
aberrant addition of nitric oxide to proteins (nitrosylation).  Dysregulated 
nitrosylation of proteins is evident in several neurodegenerative diseases, 
including AD (79). The addition of nitric oxide (nitrosylation) to the active cysteine 
of XIAP’s RING domain inactivates its E3 ligase activity.   Nitrosylated XIAP is 
unable to ubiquitinate caspases and thus unable to inhibit apoptosis (80). The 
relative amount of nitrosylated XIAP is increased in AD patient tissue, suggesting 
a role in the accelerated apoptosis observed in disease (80).   Here, then, is one 
example in which the state of the proteasome in disease is secondary to the 
decreased ability of E3 ligases to target caspases for degradation.  Therefore, it 
is essential to consider how disease-related proteins are modified by agents of 
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the USS while also examining whether affected neurons can execute the 
intended consequences of that modification.
To further illustrate the complexity of ubiquitin-mediated pathway involvement, we 
review key findings about the handling of disease-related proteins by the USS 
and UPS in several of the most common neurodegenerative diseases. 
ALZHEIMER’S DISEASE
AD is the most common form of dementia and the most common 
neurodegenerative disorder.  Its symptoms include a progressive decline in 
memory and other cognitive functions.  Histologically, AD involves extensive 
neurodegeneration and loss of synaptic connections, resulting in progressive 
atrophy of the temporal, frontal and parietal lobes of the cerebral cortex. It is 
characterized by the hallmark deposition of intracellular, filamentous aggregates 
mainly consisting of hyper-phosphorylated Tau (neurofibrillary tangles) and 
extracellular plaques rich in Amyloid-Beta (amyloid plaques) (81-83).  
Ubiquitinated forms of Tau and Amyloid-Beta, as well as other ubiquitinated 
proteins, are major components of these aggregates (84). Amyloid-Beta, 
produced by the cleavage of the Amyloid Precursor Protein (APP), is thought to 
have numerous deleterious effects on neuronal health and connectivity (85).  
Mutations in the genes encoding APP or the Presenilin protease enzymes that 
cleave APP to generate Amyloid-Beta cause early-onset AD, and support the 
notion that Amyloid-Beta metabolism is a central component of AD pathogenesis 
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(86).  The generation of hyper-phosphorylated Tau is less clearly understood. It 
has been suggested that Amyloid-Beta is able to stimulate the kinase GSK3-B, 
resulting in the aberrant phosphorylation of Tau (87). The mechanisms governing 
the synthesis, processing, and degradation of these proteins remain incompletely 
understood.  Inhibition of the proteasome causes an increase in Amyloid-Beta 
(88), and numerous studies have begun to describe an extensive role for both 
ubiquitination and the proteasome in the production and handling of APP, 
Amyloid-Beta, and Tau (Figure 3).
APP is produced in the endoplasmic reticulum (ER). HRD1, an E3 ligase 
associated with the clearance of newly synthesized proteins through ER-
associated degradation (ERAD), has been shown to interact with APP.  
Decreasing HRD1 expression evokes ER stress and apoptosis, accompanied by 
the accumulation of APP and Amyloid Beta.  The disease relevance of the HRD1/
APP relationship is supported by the reduced levels of HRD1 in AD brain tissue 
(89).  Similarly, the levels of Fbxo2, a brain-enriched E3 ligase substrate adaptor 
protein also implicated in ERAD, have been reported to be decreased in AD 
patient tissues (90).  Fbxo2 was also found to facilitate the degradation of APP, 
and a knockout mouse model for Fbxo2 revealed elevated levels of APP and 
Amyloid Beta in a brain region-specific manner (91). In the following chapter, I 
will describe the identification of APP as a substrate for Fbxo2, and the changes 
to APP levels and processing that follow the loss of Fbxo2. 
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In the Golgi apparatus, APP is ubiquitinated by unknown E3 ligases stimulated by 
ubiquilin-1, a protein with chaperone-like properties.  This ubiquitination is K63-
linked and does not cause the degradation of APP.  Instead, it causes the 
retention of APP in the early secretory pathway, impairing its maturation and 
delaying its subsequent processing by secretases into Amyloid Beta (92). The 
process by which this ubiquitination of APP is normally removed to allow 
processing remains unclear. Ubiquilin-1 levels are significantly decreased in AD 
patient brain tissues, further suggesting a role in AD pathogenesis (92). Single-
nucleotide polymorphisms (SNPs) in the UBQLN1 gene have recently been 
linked to late-onset AD (93). 
After being produced and trafficked to the surface, APP is internalized via 
endocytosis into the trans-Golgi network and sequentially cleaved to produce 
Amyloid-Beta (85). The C-terminus of HSP70 Interacting Protein (CHIP) is an E3 
ligase associated with polyglutamine neurodegenerative disorders (94,95), 
Williams 2009). In AD models, CHIP has been shown to interact with Amyloid-
Beta in the Golgi, in a manner that increases upon inhibition of the proteasome.  
Over-expression of CHIP results in a decrease in Amyloid-Beta levels and may 
stabilize levels of APP (88). 
Beyond targeting APP or Amyloid-Beta directly, the USS affects numerous other 
components of the Amyloid pathway, including the secretase enzymes 
responsible for the production of Amyloid Beta.  FBXW7 (SEL-10) facilitates the 
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ubiquitination of the gamma-secretase component Presenilin 1 (PS1), although 
this ubiquitination unexpectedly increases Amyloid Beta production through 
mechanisms that remain unclear (96).  Fbxo2, described above, has also been 
implicated in the turnover of the Beta-secretase protein BACE1 (90). 
The effects of Amyloid-Beta on neurons is also influenced by the complex actions 
of the USS. For example, the intracellular response to Amyloid-Beta is thought to 
be mediated through numerous proteins including GSK3B, a kinase that is 
reportedly increased in AD and has Tau as one of its substrates.  GSK3B has 
been investigated as a possible link between the two characteristic protein 
pathologies of AD (87). The kinase activity of GSK3B is enhanced by forming a 
complex with the tumor suppressor protein p53. Under normal conditions, this 
interaction is limited by the degradation of p53 by the E3 ligase Mouse double 
minute 2 homolog (MDM2). Under conditions of cellular stress, however, MDM2 
levels are decreased, leading to the increased association of GSK3B and p53.  
This enhancement is thought to contribute to the hyperphosphorylation of Tau 
seen in AD (97).  The observed decrease in MDM2 under conditions of stress 
actually stems from its own governance by the UPS. Under normal conditions, 
MDM2 is modified by the small, ubiquitin-like modifier protein SUMO.  
Sumoylation of MDM2 prevents its auto-ubiquitination.  Under conditions of 
cellular stress, sumoylation of MDM2 is diminished, causing it to become auto-
ubiquitinated which then triggers its own degradation by the proteasome (63). 
The level of GSK3B in neurons is also mediated by yet another E3-ligase, Nedd8 
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ultimate buster 1 (NUB1). NUB1 directly binds to GSK3B and promotes its 
degradation by the proteasome, while also inhibiting the interaction between 
GSK3B and Tau. NUB1 activity thereby diminishes the levels of hyper-
phosphorylated Tau and Tau aggregates (98). 
NUB1 was originally identified for its role in regulating Nedd8 (99,100).  Nedd8 is 
a small signaling protein similar to ubiquitin both in structure (approximately 60% 
identity and 80% homology to human ubiquitin) and in function (99,101). The 
conjugation of Nedd 8, “neddylation,” to cullin proteins promotes the 
ubiquitination activity of SCF complexes (102). Nedd8 also modifies other 
proteins, including transmembrane proteins such as APP, and may influence their 
degradation (103). Dysregulated clearance of Neddylated proteins in disease 
states is evinced by the accumulation of Nedd8 in ubiquitin-positive tau 
filamentous inclusions in some cases of AD and in Lewy bodies in Parkinson’s 
Disease (104).
CHIP, described above for its role in the turnover of Amyloid-Beta, has also been 
shown to play a role in regulating phosphorylated Tau. Through its interaction 
with two heat-shock induced proteins, Hsp70 and Hsp90, CHIP is able to 
ubiquitinate phosphorylated Tau.  Under normal conditions, this ubiquitination 
leads to an accumulation of ubiquitinated tau, which then becomes aggregated 
into high molecular-weight, detergent-insoluble aggregates. CHIP 
immunoreactivity decorates neurofibrillary tangles (NFTs) in several tauopathies, 
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including AD (105). However, over-expression of Hsp70 shifts the handling of 
ubiquitinated Tau toward a pathway of clearance through the UPS, rather than 
aggregation, and reduces Tau levels in vitro (105). Intriguingly, in vitro the 
ubiquitination of Tau also is carried out in an E3-ligase independent manner by 
the E2 Ube2w (32).  Ube2w, whose levels are increased under cellular stress, 
also ubiquitinates CHIP and regulates its activity (64).  Additionally, a role for 
CHIP in the ubiquitin-mediated turnover of caspases has been described. Mice 
which are homozygous null for Chip show increased levels of cleaved and 
uncleaved caspase-3 (106).
Although not considered causative themselves, additional proteins have been 
shown to exacerbate disease pathogenesis, and are similarly subject to 
regulation by ubiquitination.  NMDA receptors are ionotropic glutamate receptors 
whose regulated conductance of calcium into postsynaptic sites has been linked 
to learning and memory. Aberrant activation and signaling of these receptors has 
been implicated in numerous disease processes, including AD (107).  It has been 
suggested that the Amyloid-Beta-induced loss of synapses requires the activation 
of extra-synaptic NMDA receptors containing the GluN2B subunit (108,109), 
underscoring the importance of regulating NMDA receptor levels and localization 
in AD pathology. GluN2B is ubiquitinated in response to synaptic activity by the 
E3 ligase Mind Bomb-2 (110). Fbxo2, described above for its regulation of APP, 
also regulates the levels and localization of NMDA receptors in vitro and in vivo 
by facilitating the activity-dependent ubiquitination and elimination of NMDA 
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receptor subunits GluN1 and GluN2A (111). In the third chapter of this thesis, I 
will further examine the effects of Fbxo2 on synaptic content, localization, and 
transmission using an Fbxo2 knockout mouse model.
The downstream effects of NMDA receptor activation are extensive. In one 
example, following NMDA receptor activation, the cyclin-dependent kinase 5 
(Cdk5) phosphorylates Cdh1, a key regulator of the E3 ligase complex APC; in 
doing so, the turnover of its cyclin B1 by APC is inhibited, promoting neurotoxicity 
following NMDA receptor activation (112). 
PARKINSON’S DISEASE
Parkinson’s Disease (PD) is the second most common neurodegenerative 
disease and the most common neurodegenerative movement disorder. It is 
characterized by progressive abnormalities in gait and posture, as well as 
difficulty initiating and completing voluntary and involuntary movements.  
Histopathologically, PD involves the loss of dopaminergic neurons of the 
substantia nigra and locus ceruleus accompanied by astrocytosis and increased 
numbers of microglia. Throughout the brainstem of PD patients, proteinaceous 
intracellular aggregates called Lewy bodies can be found, comprised primarily of 
alpha-synuclein.  With slightly altered appearance, these synuclein-containing 
aggregates can be seen in other brain regions, and the question of their 
contribution to disease pathogenesis remains an area of intense study (113). 
Although the majority of PD cases are of sporadic origin, the small fraction of 
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inherited cases has provided valuable insight into the role of the USS and UPS in 
PD pathology (Figure 4).  
Mutations in alpha-synuclein have been described in cases of familial PD 
(114,115), and the proteasome is at least partially responsible for the turnover of 
this protein (116). Proteasome dysfunction is reported in the substantia nigra in 
PD, and proteasomal inhibition itself can cause the formation of protein 
inclusions and eventual degeneration of neurons in the substantia nigra in rats, 
although with some inconsistency (117-119). The expression of mutant alpha-
synuclein induces the formation of filaments which interact directly with the 20S 
core of the proteasome and decrease its proteolytic activity (120).  This deficit in 
proteasome function is ameliorated by the concomitant expression of the E3 
ligase Parkin (121). 
Of patients with inherited PD, nearly 40 percent of those with an early onset of 
symptoms have mutations in the gene encoding Parkin (122).  First described in 
Japan, multiple mutations in Parkin have now been described in one or both 
alleles (123). While mutations in alpha-synuclein cause autosomal dominant PD, 
mutations in Parkin cause autosomal recessive PD. These mutations result in the 
loss of Parkin function, one aspect of which is to regulate the ubiquitination of 
alpha-synuclein.  Because the accumulation of ubiquitinated alpha-synuclein is 
evident in both familial and sporadic PD, Parkin dysfunction may also play a role 
in idiopathic PD and the formation of Lewy bodies (124,125).  Consistent with this  
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view, targeted expression of mutant Parkin in disease-related brain regions of 
animal models yields similar pathologies to those observed in PD (126). 
Parkin is also involved in the intricate regulation of pro-survival signaling through 
the Akt pathway by Epidermal Growth Factor (EGF) (127). EGF-Akt signaling 
occurs through Epidermal Growth Factor Receptors (EGFR) which are 
decreased in disease-related brain regions of patients with PD (128). 
Accordingly, increased activation of EGFR in an animal model of PD prevents the 
loss of dopaminergic neurons (128). EGF signaling is regulated by ubiquitin in 
several ways. Ligand binding of the epidermal growth factor receptor (EGFR) 
stimulates Akt signaling, but triggers the endocytosis and degradation of EGFR, 
ostensibly as a means for limiting the extent of EGF signaling. This process is 
mediated by the activity-dependent ubiquitination of EGFR by an unknown E3 
ligase, which makes it eligible for recognition by the ubiquitin-interacting motif 
(UIM) of the EGFR Protein tyrosine kinase Substrate #15, Eps15.  Interaction 
with Eps15 is necessary for the internalization of EGFR, as Eps15 links 
ubiquitinated EGFRs to the machinery which traffics them to the proteasome for 
degradation (129). Parkin, which contains an amino-terminal ubiquitin-like (UBL) 
domain, blocks the Eps15-EGFR interaction by binding to the UIM of Eps15 
through this UBL domain, and then facilitating the ubiquitination of Eps15. In this 
manner, EGFR internalization is prevented, and EGF signaling and activation of 
pro-survival pathways are enhanced. But interaction between Eps-15 and Parkin 
suggests yet a further level of ubiquitin-dependent regulation.  Eps-15 promotes 
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its own ubiquitination by stimulating Parkin’s E3 ligase activity upon interaction.  
This ubiquitination, which is believed to be K63-linked, prevents the interaction of 
ubiquitinated Eps15 with other ubiquitinated proteins such as EGFR and Parkin 
itself. Notably, Parkin deficiency causes a reduction in EGF signaling (127). Here, 
again, dysfunctional ubiquitin signaling, independent of proteasomal cleavage, is 
able to regulate the health of neurons in a disease context.
Parkin has been shown to function as part of a macromolecular E3 ligase 
complex which includes the pten-induced kinase (PINK1) and the peptidase Dj-1 
(62). Mutations in both PINK1 and Dj-1 contribute to hereditary PD (130,131). 
Together, these proteins facilitate the degradation of Parkin substrates.  
Synphillin-1, which interacts with alpha-synuclein and is also present in Lewy 
bodies, is one such substrate, as is Parkin itself (62).  Additionally, the interaction 
between PINK1 and Parkin facilitates the degradation and turnover of 
mitochondria (132,133).  In order to do so, Parkin targets proteins in the outer 
mitochondrial membrane for degradation, inlcuding Tom20 (134). These findings 
suggest that Parkin dysfunction may contribute to global cellular health problems, 
even beyond the accumulation of alpha-synuclein and synphillin-1. 
Rare mutations associated with familial, early-onset PD are also found in the de-
ubiquitinating enzyme UCH-L1 (135). These mutations reduce the DUB activity of 
UCHL1. UCH-L1’s role is significant for the health and function of neurons 
through its regulation of substrates involved in governing mRNA transcription, 
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protein translation, synaptic plasticity, and pro-survival signaling. These 
processes are potently influenced by the activity of a serine/threonine protein 
kinase originally identified for its susceptibility to inhibition by Rapamycin, the 
Mammalian Target of Rapamycin, mTOR (136-139). Intriguingly, mTOR function 
requires both the correct ubiquitination of interacting proteins and proteasome 
activity (139,140). mTOR asserts its effects through the formation of large protein 
complexes. mTOR can function in combination with Raptor (mTOR Complex 1 or 
mTORC1) or Rictor (mTORC2). mTOR1 regulates transcription and is important 
for local protein synthesis, a necessary component of several types of synaptic 
plasticity. mTORC2, on the other hand, influences Akt signaling, cytoskeletal 
dynamics, and actin polymerization (141).  The balance between mTORC1 and 
mTORC2 formation depends on the interaction of Raptor with a multi-subunit E3 
ligase composed of DNA Damage-Binding Protein (DDB1), Cullin 4A (CUL4), and 
the RING-type E3 ligase RING box 1 (RBX1) (139). Although the exact 
mechanism is still unclear,  the DDB1-CUL4 complex appears to ubiquitinate 
Raptor in a manner that facilitates its incorporation into the mTORC1 complex 
including DDB1, CUL4, Raptor, and mTOR (139).  UCHL1 deubiquitinates 
Raptor, thereby destabilizing mTORC1 complex formation and shifting the 
balance toward mTORC2-dependent signaling (142).  This shift may have a 
significant impact on the ability of neurons to modify their synaptic content to 
promote learning and memory, and may also represent a neuroprotective 
response mechanism. 
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The loss of UCHL1’s DUB activity result in an accumulation of alpha-synuclein at 
presynaptic terminals rather than increased clearance (143).  Surprisingly, UCH-
L1 had been proposed to act as an E3 ligase when it self-dimerizes; this new 
activity is independent of the state of UCHL1’s DUB activity (144).  Acting as an 
E3 ligase, UCHL1 causes the K63-linked ubiquitination of alpha-synuclein, which, 
in turn, worsens PD pathology (144). Accordingly, a mutant form of UCH-L1 with 
decreased E3 ligase activity upon dimerization, but normal DUB activity, 
decreases PD pathogenesis (144).  The intended role of UCHL1’s ubiquitination 
of alpha-synuclein remains unclear. 
There have been several ubiquitin-linked proteins whose involvement in 
neurotoxicity overlaps between AD and PD. Of those described above, CHIP, 
MDM2, and HRD1 support the importance of the UPS in pathological 
mechanisms in multiple disease states. CHIP also interacts with Parkin and 
stimulates its ligase activity (145). Down-regulation of MDM2 is toxic to 
dopaminergic neurons even without a toxic insult (146).  And HRD1 levels are 
increased in dopaminergic neurons under conditions of neurotoxicity, suggesting 
a role in the response to cellular stress (147). 
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS) is the most common fatal 
neurodegenerative disease affecting motor neurons.  The loss of motor neurons 
in the brain and spinal cord of ALS patients typically results in progressive 
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paralysis and death within a few years of onset.  Non-motor pathologies, 
particularly cognitive deficits, can also accompany motor deficits. 
Histopathologically, ubiquitin-rich cytoplasmic inclusions appear in the remaining 
motor neurons of ALS patients, accompanied by marked gliosis. Ubiquitin-
positive inclusions can also be observed in cortical brain regions, consistent with 
the observed cognitive decline in many ALS patients (148,149).  Sporadic ALS 
(SALS) represents greater than 90 percent of all ALS cases, with familial ALS 
(FALS) accounting for the remaining <10 percent.  The etiology of ALS remains 
unclear, and what is known to date has been determined largely through the 
study of genes originally identified as mutated in FALS.  Importantly, the disease 
genes that cause FALS are also found mutated in some SALS cases, and the 
histopathologies of familial and sporadic cases are essentially indistinguishable 
(150), suggesting that studies of FALS will offer useful insight into all forms of 
ALS.  Among the disease genes associated with FALS, mutations in the gene 
encoding Superoxide Dismutase 1 (SOD1) were described first (151), and 
mutations in the Transactivation Response DNA-binding protein 43 (TDP-43) are 
probably the most common (152).  These two proteins accumulate in ubiquitin-
positive inclusions in disease-related neuronal populations, and the mechanisms 
of their turnover and clearance provide insight into the importance of the UPS in 
ALS (Figure 5).
SOD1 plays an important role in the elimination of free superoxide radicals. Its 
expression is regulated by several agents of the UPS.  The canonical HECT-type 
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E3 ligase E6-AP directly binds to and ubiquitinates SOD1 (153).  Levels of E6-
AP are decreased prior to the onset of neurodegeneration in a mouse model of 
ALS expressing mutant SOD1, and over-expression of E6-AP reduces the 
aggregation of mutant SOD1 in vitro (153). NEDL1, a homologue of E6-AP, is 
reported to selectively bind to mutant SOD1 but not wild-type SOD1, facilitating 
its ubiquitination and clearance (154). NEDL1 is thought to function in concert 
with the endoplasmic reticulum translocon-associated protein TRAP-δ, 
suggesting a role for NEDL1in the ERAD of mutant SOD1 (155). The interaction 
between NEDL1 and mutant SOD1 increases with disease severity, and NEDL1 
immunoreactivity is observed in SOD1-positive inclusions in human spinal cord 
tissue from FALS patients (154). Also reportedly present in SOD1-positive 
inclusions is the RING-finger type E3 ligase Dorfin, which shares NEDL1’s 
selectivity in ubiquitinating mutant, but not wild-type, SOD1 (156). Over-
Expression of Dorfin in a mouse model of FALS reduces expression and 
aggregation of SOD1 while also diminishing motor neuron degeneration (157). 
TDP-43, the major component of most aggregates in ALS cases, is normally a 
predominantly nuclear protein.  It has two RNA binding domains and has been 
implicated in RNA splicing and trafficking (158,159). Ubiquitinated TDP-43 is a 
major component of cytoplasmic inclusions in ALS (160). Mutations associated 
with ALS result in the redistribution of TDP-43 from the nucleus to the cytoplasm 
(161), although the precise mechanisms by which TDP-43 contributes to ALS 
pathogenesis remain the subject of intensive study (162). TDP-43 expression 
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inhibits proteasome function and increases levels of Parkin mRNA and protein 
(163) by binding to Parkin mRNA (164).  Parkin, in turn, is able to mediate both 
K48 and K63-linked ubiquitination of TDP-43, though this modification does not 
cause a reduction in the levels of TDP-43 (163). TDP-43 is unlike other 
substrates of Parkin-dependent K63-linked ubiquitination, which are targeted for 
degradation through the autophagic pathway (165). The interaction between 
TDP-43 and Parkin requires the histone deacetylase protein HDAC6 and 
promotes the translocation of TDP-43 from the nucleus to the cytoplasm (163). 
HUNTINGTON’S DISEASE
Huntington’s disease (HD) is the most common of the polyglutamine (polyQ) 
disorders.  While polyglutamine repeats are common motifs facilitating protein-
protein interactions, expansion of these repeats is associated with at least nine 
different neurodegenerative disorders (166,167). The threshold length at which 
this expansion begins to elicit adverse effects varies among these diseases, 
determined in part by the specific protein context neighboring the repeat in the 
expanded protein (168). Expansion of the CAG repeat in exon 1 of the gene 
coding for the Huntingtin protein increases the length of the polyglutamine 
domain (169,170).  The repeat length threshold for disease in HD is 38 or more 
repeats (171), with longer repeats causing earlier onset and more severe 
disease. Symptoms of HD include progressive cognitive impairment, mood 
disorder and other psychiatric symptoms, and highly disordered movement and 
motor control including abnormal movements such as chorea.  These 
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progressive symptoms lead to mortality within 20 years of onset (172). 
Histopathologically, HD is characterized by the degeneration of striatal and 
cortical neurons and the presence of intraneuronal, intranuclear aggregates and 
dystrophic neurites.  Both of these latter features are marked by the presence of 
ubiquitinated Huntingtin. These aggregates can be found in cortical and striatal 
neurons, with some variance in cortical localization related to the age of onset 
(173).  
The normal function of Huntingtin remains unknown.  Structural analyses and 
numerous other studies have led scientists to propose several functions including 
intracellular protein trafficking, modulation of gene transcription, and regulation of 
scaffolding proteins and NMDA receptors at the synapse (174,175). NMDA 
receptors are improperly localized to extra-synaptic sites in HD, and their 
signaling at those sites contributes to the onset of symptoms in HD animal 
models (176,177). This mislocalization decreases synaptic NMDA receptor 
activation, which has been shown to promote Huntingtin aggregation and 
neuronal survival (178).  Whether HD arises exclusively from a toxic gain of 
function for mutant Huntingtin or from an additional partial loss of normal 
Huntingtin function remains unclear.  In either case, ubiquitin plays a significant 
role in the handling of normal and mutant Huntingtin protein (Figure 6).
The presence of ubiquitinated Huntingtin suggests a failure of the UPS.  
Huntingtin is ubiquitinated (179), but it has been proposed that the proteasome 
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may be unable to process expanded polyglutamine stretches, resulting instead in 
the accumulation of peptide fragments containing polylgutamine (180). The fate 
of these peptide fragments is unclear, but they may remain associated with the 
proteasome and inhibit its function (181,182).  Intriguingly, components of the 
UPS, including proteasomes, have been identified within Huntingtin aggregates 
(183). This may represent deleterious proteasomal sequestration in aggregates, 
even though aggregation of mutant Huntingtin may itself be neuroprotective 
(178,181). The idea that Huntingtin-induced pathology includes a deficiency in 
UPS-mediated clearance is supported by the beneficial effects observed 
following efforts to increase proteasomal activity in models of HD (184).  The 
upregulation of UPS agents through the action of histone deacetylase inhibitors 
may also improve the aggregation phenotype of HD model mice (185). 
The precise mechanisms by which Huntingtin is ubiquitinated are not well 
understood. It is unclear whether, like TDP-43, ubiquitination of Huntingtin 
includes both K48 and K63 linkages.  Most studies investigating this question 
have used models over-expressing a fragment of Huntingtin with a polyQ 
expansion. While such over-expression models induce aggregation and toxicity, 
their physiological relevance to the human disease state remains an area of 
some debate. That said, in these model systems several components of the UPS 
contribute to the clearance of mutant Huntingtin. HRD1, described above for its 
role in several diseases, is implicated in the clearance of mutant Huntingtin.  The 
activity of HRD1 increases with Huntingtin polyQ expansion length, suggesting 
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that HRD1 regulation may not typically handle normal, unexpanded Huntingtin 
(186). The Tumor Necrosis Receptor Associated Factor 6 (TRAF6) is an E3-
ligase which binds to both unexpanded and mutant Huntingtin and facilitates non-
canonical ubiquitination through K6, K27, and K29-linked chains (187). The 
physiological role of this modification is unclear, but it promotes the aggregation 
of mutant Huntingtin without changing the localization of the wild-type protein. 
Additionally, NUB1, described above for its role in AD, works in conjunction with 
Cullin 3 to facilitate the ubiquitination and clearance of mutant Huntingtin (188). 
Sumoylation also can regulate HD pathogenesis. Rhes, a striatal protein which 
acts as a SUMO E3 ligase, binds to mutant Huntingtin selectively and facilitates 
its sumoylation (189).  The sumoylation of mutant Huntingtin promotes 
disaggregation; however, disaggregated, sumoylated, mutant Huntingtin inhibits 
transcription, increases cytotoxicity through Caspase-3, and may impair the 
induction of autophagy (190-192). 
Huntingtin is also reported to interact with the E2 enzyme hE2-25k (Ube2K) 
(179). The presence of Ube2k immunoreactivity in HD patient brains has been 
observed, and the Huntingtin-Ube2k interaction promotes aggregation and 
cytotoxicity in a manner that requires E2 catalytic function (193). Ube2k has been 
shown to interact with numerous RING-finger E3 ligases (194). It is possible that 
Ube25k cleaves the polyubiquitin chains attached to Huntingtin to an extent that 
degradation is no longer signaled.
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CONCLUSIONS: TOO BIG NOT TO FAIL
Befitting its extensive contributions to a wide range of cellular processes, the 
systems of protein ubiquitination and ubiquitin-dependent clearance are 
implicated at many levels of the most common neurodegenerative disorders. Is 
this implied involvement in disease incidental, or does dysregulated ubiquitination 
and clearance represent an inevitable and common pathway for the worsening of 
all neurodegenerative diseases? Because alterations in ubiquitin-dependent 
gene transcription, translation, control of protein quality and maturation, 
trafficking, mitochondrial turnover, and the handling of protein-protein interactions 
are found in combination in neurodegenerative disease, it seems likely that 
dysregulated ubiquitination will not remain limited to a single ubiquitin-dependent 
process in a given disease.  Instead, the UPS and USS will be widely involved. 
To what degree this involvement might begin the pathogenic cascade is currently 
unclear. But based on the studies reviewed here, it seems more likely that 
through a complex web of dysfunction in the UPS and USS, involvement of these 
systems causes the pathogenicity of aberrant proteins to diversify and flourish, 
affecting additional systems and promoting the loss of synapses and cell death.
The UPS is not alone in its handling of unwanted or toxic proteins. The 
autophagic system is the other major pathway by which protein clearance is 
achieved. Autophagy especially regulates the turnover of organelles and 
aggregated protein species, and accordingly its role in neurodegenerative 
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disease has been extensively pursued.  Upon failure of the proteasome, 
autophagic mechanisms can be induced as a compensatory response to UPS 
inhibition in numerous neurodegenerative diseases (195-197). Further activation 
of autophagic mechanisms through pharmacologic or genetic manipulation has 
proven useful as a therapeutic intervention in model systems (198).   It seems 
evident, however, from the continued accumulation of ubiquitin-positive proteins 
in neurodegeneration, that autophagic induction is not sufficient to overcome this 
failure. Moreover, it is unclear what effect sustained, heightened autophagy might 
have on already weakened neurons.  
The overlapping involvement of certain E3 ligases like HRD1, NUB1, and CHIP 
not only speaks to their significance as key regulators of proteostasis but also 
nominates them as important targets for research.  While knocking out CHIP has 
been shown to exacerbate polyglutamine pathology (95), CHIP over-expression 
can reduce proteotoxicity and the effects of cellular stress in numerous models 
((94,199,200).  But CHIP induction without concurrent upregulation of Hsp70 
might worsen tau pathology, suggesting that combinatorial approaches to therapy 
will be required. 
In considering the specific goals and appropriate timing for interventions intended 
to prevent or delay disease onset, it is important to acknowledge that the loss of 
synapses precedes neurodegeneration and is thought to underlie many of the 
earliest cognitive impairments in numerous diseases.  As such, it may represent 
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a key step in the disease cascade and a critically important target for therapies. 
Alternatively, synaptic connections may simply be too costly for unhealthy 
neurons to properly maintain, and the loss of synaptic connections is, in effect, a 
response intended to limit inappropriate and potentially dangerous synaptic 
signaling in disease states. In the latter case, this dauer-like state is ultimately 
ineffective in staving off neurodegeneration, but may slow the process. With 
respect to human disease, perhaps restoring synapses could improve quality of 
life - regardless of whether such a change ultimately lengthens or shortens the 
life-span of affected neurons.  For this reason, elucidation of the processes by 
which ubiquitin governs synapse formation, maintenance, and removal under 
normal conditions may prove invaluable. 
 
FIGURE LEGENDS
Figure 1. The Process of Ubiquitin Conjugation
1. Ubiquitin (U) is bound via a thioester bond to the active-site cysteine of an E1 
Ubiquitin-Activating enzyme, through a process requiring ATP. 2. The ubiquitin 
molecule is then passed to an E2 Ubiquitin-Conjugating Enzyme through trans
(thio)esterification. 3. An E3 ubiquitin ligase brings the E2 into sufficiently close 
proximity and correct alignment with a substrate protein to facilitate the transfer 
of ubiquitin to a target residue.  In the case of HECT-type E3s, the ubiquitin is 
first transferred to an active site cysteine on the E3 before being conjugated to 
the substrate.  E3s can also exist as multi-subunit complexes including 
scaffolding and adaptor proteins that confer substrate specificity to the process of 
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ubiquitin transfer.  4. Additional ubiquitin molecules can be added onto the first to 
create polyubiquitin chains on substrate proteins. 
Figure 2. The Ubiquitin Proteasome System
The 26S proteasome is composed of a cylindrical, proteolytic 20S core which is 
capped at both ends by a 19S regulatory cap.  Polyubiquitinated substrate 
proteins, typically bearing K48-linked chains, are targeted to the proteasome by 
trafficking proteins.  The proteasome digests these substrates into smaller 
peptides and free ubiquitin molecules, which then can be used to modify further 
substrates.
Figure 3. Regulation of Protein Trafficking, Receptor Signaling, and Protein 
Clearance by Ubiquitination
Improper processing of APP and Tau contribute to the pathology of AD. 
Excessive or improperly folded APP is cleared from the ER by HDR1 and Fbxo2 
through the addition of K-48 linked chains. Ubiquitin-mediated processes are 
indicated by dashed lines.  Maturation of APP is arrested in the early secretory 
pathway by non-degradative, K-63 linked ubiquitination that is stimulated by 
Ubiquilin 1. Surface APP is endocytosed to the late Golgi, where it is cleaved by 
secretases including BACE-1 and PS-1, whose levels are regulated by the E3 
ligases Fbxo2 and FBXW-7, respectively.  The cleavage of APP results in the 
production of Amyloid-Beta, which can be targeted for degradation by CHIP.  
Uncleared Amyloid-Beta is exocytosed to the extracellular space, where it 
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aggregates to form plaques.  Amyloid-Beta can influence NMDA receptor 
signaling.  NMDA receptor activation stimulates the kinase Cdk5, which results in 
the downstream inhibition of the E3 ligase APC and blocks the degradation of 
cyclin B1. NMDA receptor signaling also increases the activation of GSK3B, 
which phosphorylates Tau.  GSK3B is targeted for degradation by NUB1, which 
also blocks the interaction between GSK3B and Tau. GSK3B activity is increased 
by complexing with p53, whose levels are regulated by the E3 ligase MDM2.  
Under conditions of cellular stress, MDM2 auto-ubiquitinates and targets itself for 
degradation.  The E3 ligase CHIP targets Tau, but can have divergent effects on 
its handling.  When working in combination with Hsp70, CHIP targets Tau for 
degradation.  However, when Hsp90 is involved, CHIP facilitates an alternative 
ubiquitination of unknown linkage type, resulting in the accumulation of 
phosphorylated tau.  Through an unknown mechanism, this accumulated Tau 
then forms insoluble protein aggregates. 
Figure 4. Ubiquitination in Pro-survival Pathways, Mitochondria Stability, and 
Protein Clearance in Parkinson’s Disease
Dysregulation of Parkin and UCHL1, both of which are associated with PD, has 
widespread effects on neuronal health. The Epidermal Growth Factor (EGF) 
binds to EGFR and initiates pro-survival signaling through the Akt and mTOR 
pathways.  Ligand-binding to EGFR stimulates its ubiquitination, which allows for 
its UIM-dependent recognition by Eps15.  Eps15 internalizes EGFR, allowing it to 
be trafficked to the proteasome for degradation.  The EGFR-Eps15 interaction is 
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blocked by the interaction of the UBL of the E3 ligase Parkin with the UIM of 
Eps15; this interaction increases Parkin’s ligase activity, causing Eps15 to 
become ubiquitinated and dissociated from its UIM-dependent interactors. 
Downstream of EGFR signaling, mTOR’s participation in the protein complex 
mTORC1 requires the ubiquitination of Raptor by DDB1 and Cul4.  This 
ubiquitination is undone by the de-ubiquitinating enzyme UCHL1. Parkin also 
plays a role in the degradation of mitochondrial outer membrane proteins 
including Tom20, and through its involvement with PINK1 and Dj-1, facilitates the 
degradation of Synphilin-1 and itself. Synphilin interacts with alpha-synuclein, 
which can be degraded by Parkin in association with CHIP.  Dimerized UCHL1 
may also modify alpha-synuclein, though the result is non-degradative, K-63 
linked ubiquitination which promotes its accumulation.  Accumulated alpha-
synuclein binds to the 20S core of the proteasome and inhibits proteasome 
function. 
Figure 5. A Role for Ubiquitination in the Pathogenesis of Amyotrophic Lateral 
Sclerosis
Impaired turnover of SOD1 and TPD-43 are implicated in the etiology of ALS. 
Mutated or excess SOD1 in the ER is targeted for degradation by the E3 ligase 
NEDL1 via the translocon protein TRAP. SOD1 in the cytosol is targeted by the 
canonical HECT-type E3 ligase, E6-AP, and the RING-type E3 Dorfin. TDP-43 
can be ubiquitinated by Parkin in association with HDAC6. This modification can 
include both K48 and K63-linked chains and does not lead to the degradation of 
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TDP-43, instead increasing the proportion of TDP-43 in the cytosol.  In the 
nucleus, TDP-43 regulates the transcription of genes including Parkin. In the 
cytosol, accumulated TDP-43 can inhibit the proteasome and form protein 
aggregates.
Figure 6. Ubiquitin-mediated Handling of the Pathologic Huntingtin Protein in 
Huntington’s Disease 
The Huntingtin protein is improperly cleared from neurons in HD. Mutant 
Huntingtin can be targeted for degradation in the ER by HRD1, and in the cytosol 
by NUB1.  However, this ubiquitination can be edited by UCHL1, inhibiting the 
degradation of Huntingtin and promoting its aggregation in the cytosol. Traf6 
facilitates the non-canonical ubiquitination of Huntingtin through the formation of 
K6, K27, and K29-linked polyubiquitin chains, and these modifications selectively 
promote the aggregation of mutant Huntingtin. Aggregates of mutant Huntingtin 
include components of the UPS including proteasomes. Rhes promotes the 
sumoylation of Huntingtin, which promotes its  disaggregation but then causes 
mutant Huntingtin to interfere with other cellular processes including gene 
transcription in the nucleus. 
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Chapter Two: F-box only protein 2 (Fbxo2) Regulates Amyloid Precursor 
Protein Levels and Processing
ABSTRACT
The Amyloid Precursor Protein (APP) is an integral membrane glycoprotein 
whose cleavage products, particularly Amyloid-β, accumulate in Alzheimer’s 
Disease (AD). APP is present at synapses and is thought to play a role in both 
the formation and plasticity of these critical neuronal structures. Despite the 
central role suggested for APP in AD pathogenesis, the mechanisms regulating 
APP in neurons and its processing into cleavage products remain incompletely 
understood. F-box only protein 2 (Fbxo2), a neuron-enriched ubiquitin ligase 
substrate adaptor that preferentially binds high-mannose glycans on 
glycoproteins, was previously implicated in APP processing by facilitating the 
degradation of the APP-cleaving beta-secretase, beta-site-APP-cleaving enzyme 
(BACE1).  Here we sought to determine whether Fbxo2 plays a similar role for 
other glycoproteins in the amyloid processing pathway. We present in vitro and in 
vivo evidence that APP is itself a substrate for Fbxo2. APP levels were decreased 
in the presence of Fbxo2 in non-neuronal cells, and increased in both cultured 
hippocampal neurons and brain tissue from Fbxo2 knockout mice.  The 
processing of APP into its cleavage products was also increased in hippocampi 
and cultured hippocampal neurons lacking Fbxo2. In hippocampal slices, this 
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increase in cleavage products was accompanied by a significant reduction in 
APP at the cell surface. Taken together, these results suggest that Fbxo2 
regulates APP levels and processing in the brain and may play a role in 
modulating AD pathogenesis. 
INTRODUCTION
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder. Its 
progressive brain pathology robs patients of memory and cognitive abilities 
through complex mechanisms that remain unclear. Abnormalities in the 
processing of Amyloid Precursor Protein (APP) are thought to play a central role 
in AD pathogenesis (1), largely based on the fact that mutations in APP and the 
APP cleavage enzyme gamma secretase cause early-onset familial AD and 
replicate key disease features in animal models, including the accumulation of 
Amyloid Beta (Aβ) peptide (2). Generated from proteolytic processing of APP (3), 
Aβ is the major component of the characteristic amyloid plaques that accumulate 
in AD. Aβ has also been shown to alter synaptic function and decrease synapse 
numbers (4).  Indeed, the loss of synaptic connections more closely correlates 
with cognitive deficits observed in AD patients than does the loss of neurons and 
cortical thinning observed later in AD (5).   
The regulation of APP expression and processing is critically important to the 
development and progression of AD.  APP is sequentially cleaved by a series of 
secretase enzymes through a complex process linked to neuronal metabolism 
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and activity (6). Factors that increase the amount of APP available for cleavage 
inversely correlate with the age of onset of dementia and AD-like pathology (7). 
For example, patients with trisomy 21, a triplication of the chromosome harboring 
the APP gene, develop early onset dementia with characteristic AD pathology, 
which is not observed in patients with partial trisomy excluding the APP gene (8).  
Genetic studies in animal models further support the notion that increased APP 
expression or processing, either through gene duplication or mutation, can lead 
to early onset dementia with AD-like pathologies (9). 
The correlation of APP levels and APP processing to AD pathogenesis 
underscores the importance of understanding how neurons regulate APP levels 
and subcellular localization. The importance of APP, moreover, extends beyond 
its disease link: APP also plays numerous roles in neuronal function and 
development. Synapse formation and localization, maintenance of dendritic 
spines, neurite outgrowth, synaptic plasticity, and neuronal survival are all 
influenced by APP (10-14). Cleavage of APP is regulated by neuronal activity, 
and its cleavage products in turn seem to regulate neuronal activity, although the 
precise function of this feedback remains uncertain (15). 
The current study seeks to define pathways that regulate APP levels in neurons, 
focusing on Fbxo2, a brain-enriched, ubiquitin ligase adaptor subunit that 
specifically recognizes glycoproteins containing high mannose glycans (16).  As 
a type 1 transmembrane glycoprotein, APP is synthesized in the cytoplasm and 
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translocated into the endoplasmic reticulum (ER) where it achieves native folding 
and becomes glycosylated. Properly folded and glycosylated APP then transits 
from the ER to the Golgi apparatus for further modification, and is eventually 
delivered to the plasma membrane. APP is known to undergo rapid and constant 
bulk turnover (17); the extensive, newly synthesized APP that is continually 
produced by neurons must be appropriately governed for protein quality control 
purposes. ER-associated-degradation (ERAD) is a normal cellular process by 
which uncomplexed or improperly modified proteins are removed from the ER 
and degraded by the ubiquitin proteasome system (UPS). The ERAD ubiquitin 
ligase HRD1 has already been shown to play a role in clearing mutant or 
misfolded APP from the ER (18). Knocking down this ligase increases APP levels 
and promotes Aβ generation.  Whether HRD1 is the only ubiquitin ligase that 
mediates APP clearance from the ER remains uncertain.
For several reasons, Fbxo2 is an attractive candidate to contribute to APP.   First, 
it is a neuron-enriched ubiquitin ligase substrate adaptor protein that binds 
glycoproteins containing high mannose N-linked glycans and facilitates their 
degradation through ERAD (19). Second, Fbxo2 was recently shown to decrease 
levels of the beta secretase enzyme, BACE1, which is essential for Aβ 
generation, in an N-linked glycan-dependent manner (20). Over-Expression of 
Fbxo2 resulted in decreased BACE1 levels, in turn diminishing Aβ production.  
And third, levels of Fbxo2 are decreased in AD patient brains, raising the 
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intriguing possibility that age-related reduction in Fbxo2 levels might accelerate 
the amyloid process (20).
Although substrate specificity is conferred by ubiquitin ligases and their adaptors, 
an individual ligase can have numerous substrates.  Here, using cell based 
studies and Fbxo2 knockout (Fbxo2 -/-) mice, we show that Fbxo2 also regulates 
additional glycoproteins beyond BACE1 in the amyloid precursor pathway, 
specifically APP itself and the alpha secretase enzyme, ADAM10.  Our results 
suggest that the loss of Fbxo2 results in dysregulation of glycoprotein 
homeostasis in neurons with implications for APP processing.  
EXPERIMENTAL PROCEDURES
Animals – Fbxo2 -/- mice were previously generated through targeted deletion of 
the first five of six exons encoding Fbxo2. These mice were backcrossed to a 
C57BL/6J background and exhibited no abnormalities in brain size, weight, 
development, or adult gross brain structure, though they developed cochlear 
degeneration (21).
DNA Constructs, HEK Cell Culture, and Lysate Preparation – HEK-293 cells 
were cultured and maintained as previously described (22). For expression in 
HEK-293 cells, constructs for full-length APP (produced by D. Selkoe, Addgene 
plasmid 30154), Myc-Adam10 (produced by R. Derynck, Addgene plasmid 
31717), BACE1 (Origene, clone SC115547) or Fbxo2 (gift of K. Glenn, Univ. 
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Iowa) were transfected with Lipofectamine 2000 (Invitrogen) as per 
manufacturer’s directions.  48 hours after transfection, cells were collected in hot 
denaturing lysis buffer containing 2% SDS and 100mM DTT. Lysates were boiled 
for five minutes, centrifuged, and loaded onto 4-15 or 4-20% gradient SDS-PAGE 
gels (Biorad). 
Brain Extraction/Lysis – For western blot experiments, animals were anesthetized 
with ketamine/xylazine and cardiac perfused with pre-warmed phosphate-
buffered saline (PBS).  Mice were then decapitated and their brains removed.  
When required, hippocampi were rapidly dissected under a dissecting 
microscope. Tissues were then lysed in hot SDS (2%) lysis buffer with 100mM 
DTT in a dounce homogenizer, centrifuged, and boiled for five minutes.  Protein 
concentrations were determined using a quantification kit (Macerey-Nagel, 
Duren, Germany) and equal amounts were loaded and run on 4-15 or 4-20% 
SDS-PAGE gels. For ELISA experiments, brains or hippocampi were lysed in 
cold RIPA buffer with protease and phosphatase inhibitors (Roche) in a dounce 
homogenizer, centrifuged, and kept on ice for immediate analysis.
Western Blotting – Proteins were immunoblotted using antibodies against APP 
(22C11, Millipore) or its C-terminal fragments (polyclonal anti-APP cytoplasmic 
domain G369 antibody, a gift from S Gandy), Fbxo2 (a gift from K. Glenn, Univ. 
Iowa, directed against an amino-terminal domain of Fbxo2), Myc (Santa Cruz), 
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BACE1 (gift from R Vassar), Transferrin Receptor (Invitrogen), Caspase-3 (Cell 
Signaling) or GAPDH (Millipore).  
ELISAs – RIPA buffer-homogenized lysates and collected media were analyzed 
using ELISA kits according to the manufacturer’s instruction.  For brain tissue, 
Aβ42 (high sensitivity, Wako) and sAPPα (IBL) kits were used. For collected 
media from neurons, soluble APP (sAPPα) (IBL), Aβ40 (Invitrogen), and Aβ42 
(Novex/Life Technologies) were used.
Immunohistochemistry of frozen brain sections – Briefly, mice were processed as 
for brain extraction, but were perfused with 4% paraformaldehyde in PBS 
following the PBS flush.  Upon removal, brains were post-fixed, rinsed, and 
cryopreserved.  Once frozen, they were cut into 12 micron sections and 
preserved at minus eighty degrees until use. Alexafluor 488 (Invitrogen) was 
used to visualize 22C11 staining and sections were imaged on a Nikon A1 
confocal microscope.  All lower intensity images were collected at the same laser, 
offset, and detection intensity regardless of brain region. Higher intensity images 
were generated by increasing the brightness equally for all pixels in all images in 
Fiji Image J. Z-stack images were collected through equal stack dimensions. 
Images were cropped using Photoshop CS3 (Adobe). Heat maps were 
generated in Fiji Image J with the Rainbow RGB lookup table. The CA1 region of 
hippocampus and the portion of visual cortex (V1/V2) directly lateral and superior 
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to CA1 were imaged. Three mice at the six month time point were used for 
imaging.
Acute Slice Biotinylation – Surface levels of proteins were compared to total 
amounts as previously described (23).  Briefly, mice were anesthetized and their 
brains removed.  Hippocampi were rapidly dissected in ice cold, oxygenated 
artificial cerebrospinal fluid (ACSF).  350 µm slices were then cut using a 
MacIlwain Tissue Chopper, and alternating sections from both hippocampi were 
placed into cold, oxygenated ACSF with or without EZ-Link Sulfo-NHS-LC-biotin 
(Pierce).  After 45 minutes, slices were washed in artificial cerebrospinal fluid 
(ACSF) and any unbound biotin was quenched by incubating the slices in lysine.  
Following additional washes, the non-biotinylated slices were homogenized in 
SDS (2%) lysis buffer with 100 mM DTT using a dounce homogenizer.  Lysates 
were then boiled and centrifuged and retained at -80º C as the “total” fraction.  
Slices with biotin were lysed in buffer containing 1% TX-100, 0.1% SDS, 1 mM 
EDTA, 50 mM NaCl, 20 mM Tris, pH 7.5, with protease inhibitors (Roche) in a 
glass homogenizer.  Biotinylated proteins were then precipitated by the addition 
of Streptavidin Resin (Pierce) and overnight incubation at 4º C on a rotating 
platform. Precipitates were then collected by first centrifuging to separate 
supernatant from resin, then boiling the resin in SDS (2%) lysis buffer with 
100mM DTT.  The resulting “surface” fraction was retained at minus eighty 
degrees until being analyzed.  30 µg of protein from each “total” fraction was run 
alongside 2 µg of enriched “surface” protein.  
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Hippocampal Neuron Culture and Immunofluorescence – Hippocampal neurons 
were obtained and cultured from pups 3 days postnatal, maintained, and 
immunostained as previously described (24).  All neurons were analyzed at 14 
days in vitro (DIV14). Antibodies against APP (22C11, Millipore), Vesicular 
Glutamate Transporter (Vglut) (Millipore), Spinophilin (Millipore), PSD-95 
(Abcam), and Binding Protein (BiP) (Abcam) were visualized using AlexaFluor 
488, 568 or 647 secondary antibodies (Invitrogen).  Confocal z-stack images 
were collected using an A-1 confocal microscope (Nikon) at the University of 
Michigan Microscopy and Image Analysis Laboratory.
Quantification and Statistical Analysis – Immunoblot results were scanned into 
Adobe Photoshop and measured using ImageJ software.  Prism 6 software 
(GraphPad) was used for statistical analysis and to generate graphs.  
Immunofluorescence data was analyzed using ImageJ as previously described 
(25). 
RESULTS
Fbxo2 has been implicated in the clearance of BACE1 (20). To determine 
whether Fbxo2 facilitates the degradation of other key glycoproteins in the 
amyloid processing pathway, we expressed constructs encoding full-length APP 
or a Myc epitope-tagged form of the alpha-secretase ADAM10 in HEK cells 
together with empty vector or FLAG-tagged Fbxo2 (Fig7). BACE1, already 
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established as an in vitro substrate for Fbxo2, was included as a positive control 
(Fig7, c).  Co-expression of Fbxo2 resulted in a marked decrease in steady-state 
levels of each co-expressed substrate as measured by western blot.  The 
antibodies for APP and ADAM10 detect bands for both immature, high mannose 
glycan-bearing and mature, complex glycan-bearing forms of the protein on 
western blot.  Levels of APP are significantly decreased when co-expressed with 
Fbxo2 (Fig7, a). A similar reduction is seen when Fbxo2 is co-expressed with 
ADAM10, with the immature form of ADAM10 being further reduced (Fig7, b)(26). 
These ADAM10 results are consistent with the canonical view of the role of 
Fbxo2 in ERAD, as immature forms of these proteins still carry high mannose 
glycans (the major ligand for Fbxo2), which are later processed to complex 
glycans in the Golgi apparatus.
As Fbxo2 is a brain-enriched protein (27), we next sought to determine whether 
these APP pathway components, identified here as Fbxo2 substrates in 
heterologous, non-neuronal cell systems, are also physiologically relevant in 
neuronal cells. Cultured neurons isolated from wild-type and Fbxo2 knockout 
mice previously generated in our lab offer three distinct advantages for 
addressing this question: First, we are able to measure endogenous proteins 
without the confounding factor of transient over-expression; second, media 
collected from cultures provides a feasible and practical way to assess the 
processing of APP into its secreted cleavage products; and third, neurons are 
more easily visualized in culture than in vivo, allowing for a better assessment of 
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any potential differences in the localization of APP.  Primary cultures of 
hippocampal neurons were prepared from mice at postnatal day 3. Cultured 
neurons lacking Fbxo2 differed markedly from wild-type neurons in several 
respects. Compared to levels in wild-type cultured neurons, total APP levels were 
elevated in Fbxo2 -/- neurons as revealed by Western blot (Fig 8, a). ELISA 
assessment of media collected from Fbxo2 -/- neuronal cultures revealed more 
than double the levels of secreted Aβ40, Aβ42 and sAPPα (Fig 8, b).  The ratio of 
Aβ40 to Aβ42 remained unchanged, with both metabolites increasing 
proportionately (Fig 8, b). Neither ADAM10 nor BACE1 levels differed between 
wild-type and Fbxo2 knockout neurons (data not shown).
We next examined the distribution of the increased APP observed in Fbxo2 null 
neurons (Fig 9). Quantitative immunofluorescence showed that while APP levels 
were higher throughout Fbxo2 -/- neurons, APP accumulated to a greater degree 
in dendrites than in soma (Figure 9, a, d). Immunoreactive APP puncta were 
observed along dendrites with greater frequency and size than in wild-type 
controls. Consistent with previous studies describing APP trafficking to synapses 
(28), APP puncta in dendrites colocalized with the pre- and post-synaptic markers 
Vglut and Spinophilin (Fig 9 a, b).  Remarkably, the amount of synaptic marker-
positive puncta, additionally measured with the postsynaptic scaffolding protein 
PSD95, was significantly increased in neurons lacking Fbxo2 (Fig 9, c, d). BiP, an 
ER-resident protein whose accumulation is indicative of ER stress, was not 
increased in knockout neurons (Fig 9, d). Caspase 3, a cytosolic protein whose 
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cleavage is believed to play a role in apoptosis, was also assessed by western 
blot (Fig 9, d).  No difference in the level of uncleaved caspase-3 was observed 
between wild-type and knockout neurons, and no cleaved Caspase 3 was 
detected for either genotype. These results suggest that the loss of Fbxo2 does 
not cause pathological consequences for neuronal health, nor does it universally 
affect protein expression. 
Having identified several changes in APP handling in cultured neurons, we next 
assessed these changes in the intact brain. Examination of brains from wild-type 
and Fbxo2 knockout mice at several ages revealed age-dependent differences. 
We observed a significant increase in endogenous APP levels in Fbxo2 knockout 
mouse brain at three and six months of age as measured by western blot from 
whole brain lysates (Fig 10, a).  The time course of this difference is consistent 
with the onset of murine Fbxo2 expression during the first month of age. We next 
sought to visualize the difference in APP expression between wild-type and 
knockout mice.  In cortex at six months, anti-APP immunofluorescence confocal 
imaging revealed that both the cell bodies of cortical neurons and the 
surrounding neuropil are more strongly labeled in knockout cortex than in control 
cortex (Fig 11, a).  Image brightness was equally increased (Figure 11, c) to help 
visualize the comparatively less-bright staining in wild-type mice. Whereas in 
vitro we observed a shift toward higher dendritic expression, in vivo we observe 
increased expression throughout the cell bodies and neuronal projections of the 
cortex. 
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ELISA experiments were used to assess whether the increased steady-state 
levels of APP seen in Fbxo2 knockout mice corresponded to an increase in 
cleavage products.  No change in the amyloid cleavage products Aβ42 and 
sAPPα was observed at the level of whole brain (Fig 10, b, c). However, since 
amyloid cleavage products are rapidly removed from the brain through enzymatic 
degradation, glial uptake, and cerebrospinal fluid (CSF) clearance (29), attempts 
to quantify secreted amyloid cleavage products by measuring brain tissue lysates 
can be confounded by these factors, making it difficult to gauge fully the extent of 
the role played by Fbxo2 in brain tissue. No differences were observed at three 
or six months of age in the levels of APP C-terminal fragments (CTFs) C99, C89, 
or C83 (Fig 10, d).  It is possible that knockout mice have no difficulty limiting 
these fragments to appropriate levels.
The previous study linking Fbxo2 to the regulation of BACE1 employed transient 
shifts in Fbox2 levels, either through heterologous cell expression or over-
expression in mice (20).  As shown earlier in Fig1, we similarly used transient 
expression to demonstrate facilitated degradation of BACE1 by Fbxo2 and to 
identify ADAM 10 as an additional Fbxo2 substrate.  When Fbxo2 is constitutively 
knocked out in the mouse, however, we did not detect any alteration in 
endogenous BACE1 or ADAM10 levels (Fig 10, e, f).
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Fbxo2 is expressed throughout the brain, but at higher levels in forebrain and 
midbrain than in hindbrain (27). AD preferentially affects specific brain regions 
including the hippocampus (30). To test whether the effects of Fbxo2 knockout on 
APP pathway components were more pronounced in this disease-relevant 
region, hippocampi were dissected and similarly assessed for APP levels.  At 
three and six months of age, there was no statistical difference in total APP 
observed between Fbxo2+/+ and Fbxo2 -/- in the hippocampus (Fig 12, a).  
Consistent with our western blot data, anti-APP immunofluorescence of the 
hippocampus did not reveal a significant difference between wild-type and 
knockout mice (Fig 12, e). There was, however, a significant increase in 
hippocampal levels of Aβ42 at three months of age in Fbxo2 -/- mice and a non-
statistically significant trend toward increased sAPPα (Fig 12, c). The observation 
that the whole brain of Fbxo2 -/- mice carries more uncleaved APP (Fig 10, a) 
while the hippocampus carries more APP cleavage products may reflect regional 
differences in neuronal activity and amyloid processing, as previously described 
(15). In such a scenario, we might expect to see this change reflected in 
increased levels of CTFs of APP in Fbxo2 knockout mouse hippocampus. We did 
not, however, observe differences in the levels of CTFs between wild-type and 
knockout hippocampi at three or six months (Fig 12, d), despite a level of amyloid 
beta in knockout hippocampus at three months which is 50% greater than it is in 
wild-type hippocampus. Taken together, these data suggest that there are region-
specific responses to the effects of eliminating Fbxo2.
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Aβ is primarily generated from APP that has been endocytosed from the cell 
surface and transported to the trans-Golgi network where it is cleaved by BACE1 
(11,31-33). Alterations to surface APP levels have been shown to affect Aβ 
production (31,33).  To determine whether the increase in amyloid cleavage 
products observed in three-month-old hippocampus corresponds to a decrease 
in surface APP, we performed in vivo biotinylation of acute hippocampal slices 
from three-month old mice, a technique that allows one to estimate the cell 
surface versus intracellular pools of APP or other protein of interest. In contrast to 
the lack of change in total hippocampal APP, the amount of surface APP in the 
hippocampus of Fbxo2 -/- mice was indeed significantly decreased compared to 
wild-type controls (Fig 13, b).  The Transferrin Receptor (TfR) was used as a 
control glycoprotein known to have some surface expression, and no difference 
in the amount of surface TfR was observed between genotypes. These results 
suggest that although total levels of APP appear unaltered in the hippocampus of 
Fbxo2 knockout mice, the handling of APP with respect to its surface localization 
is significantly different, which may reflect increased processing into Aβ. 
DISCUSSION
Here we describe a broader role for Fbxo2 than previously recognized in 
handling glycoprotein turnover relevant to APP processing.  The constant 
demand for newly produced APP in neurons requires optimal protein quality 
control, and ERAD provides an effective means of clearing unwanted, immature 
glycoproteins still bearing high-mannose glycans. As a brain-enriched ubiquitin 
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ligase adaptor subunit, Fbxo2 binds to such glycans on immature glycoproteins 
and facilitates their ubiquitin-dependent degradation. In the current study, we 
combined cell-based and animal models to show that Fbxo2 contributes to the 
regulation of both the steady-state levels of APP and its cleavage products. 
Our results in cell-based, transient expression models support previous work (20) 
implicating Fbxo2 in handling BACE1 and extend Fbxo2 activity to two other 
critical amyloid pathway glycoproteins, APP and ADAM10. There are, however, 
important differences between our cell-based findings and our results in Fbxo2 
knockout mice that underscore the importance of combining in vitro and vivo 
studies when seeking to define the role of a ubiquitin pathway protein like Fbxo2.  
Over-Expression in transient systems may elicit protein behaviors and protein-
protein interactions not readily observed under normal, or more physiological, 
conditions. The fact that we do not see changes in BACE1 in Fbxo2 knockout 
mice does not necessarily conflict with the previously findings by Gong et al (20).  
Their studies employed transient changes to Fbxo2 levels in vivo and in vitro, 
and similarly, our transient over-expression studies in heterologous cell models 
strongly support the view that Fbxo2 facilitates the degradation of BACE1. The 
same is true for our transient expression studies showing Fbxo2 activity toward 
ADAM10.   Under more physiologic conditions with endogenous ADAM10 and 
BACE1, however, no such effects are observed in Fbxo2 knockout mice. We 
suggest that the lifelong deprivation from Fbxo2 occurring in Fbxo2 -/- mice 
expressing endogenous levels of BACE1 and ADAM10 may elicit redundant 
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cellular mechanisms by which these proteins are regulated, resulting in only a 
partial effect of Fbxo2 absence on APP levels and no observed effect on BACE1 
or ADAM10 levels in vivo. In the future, conditional Fbxo2 knockout models could 
be utilized to address the discrepancy between previous in vitro data and the in 
vivo data presented here.
Our results suggest APP may be processed more extensively in Fbxo2 -/-
hippocampus than in wild type hippocampus, as there is an increased amount of 
Aβ compared to cortex with a decreased amount of total APP.  In opposition to 
this idea, we were unable to detect an increase in APP C-terminal fragments in 
cortex or hippocampus at three or six months. While this seems counter-intuitive 
for the time point at which increased Aβ is observed, the processes by which 
these fragments are cleared are not entirely understood, although they may 
involve autophagic mechanisms. In Fbxo2 knockout mice, presumably any 
excess in CTFs above the normal amount found in wild-type mice are cleared 
through a non-Fbxo2 dependent manner as they no longer contain glycans.   
There is brain region selectivity regarding the effect of Fbxo2 absence on the 
steady-state levels of APP as revealed by immunohistochemistry.  In the cortex, 
imaging reveals strong staining for APP within neurons and throughout the 
neuropil.  In the hippocampus, however, the signal is markedly less than that 
observed in the cortex, consistent with our finding that in Fbxo2 -/- mice, full-
length APP is increased in whole brain but not in the hippocampus per se.  With 
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no apparent difference in the level of Fbxo2 expression between cortex and 
hippocampus of wild type mice, it remains to be determined why the loss of this 
protein would result in differing effects on a substrate in distinct brain regions.
Given the absence of changes to BACE1 and ADAM10 levels in Fbxo2 knockout 
mice, the apparent increased cleavage of APP in the hippocampus of knockout 
mice becomes more difficult to explain. If, in the absence of Fbxo2, APP 
bypasses ERAD and transits from the ER to the cell surface where it is 
subsequently endocytosed and cleaved, then we would anticipate that the ratio of 
surface to total APP might remain the same while seeing an increase in total 
cleavage products. Essentially both APP and its cleavage products would 
increase, as observed in our cultured hippocampal neurons. In Fbxo2 knockout 
hippocampal neurons, however, the intracellular pool of APP and the cleavage 
products are both increased, presumably at the expense of the surface pool. 
What might cause the surface pool of APP to become more rapidly depleted in 
Fbxo2 knockout mice remains to be determined.  Conceivably, the absence of 
Fbxo2 drives excess APP to the neuronal cell surface, but into a different 
subregion of the plasma membrane or in an altered conformational state that 
allows it to be endocytosed and cleaved at a greater rate. Further analysis of 
Fbxo2 -/- mice may reveal whether, for example, there is preferential distribution 
of surface APP to lipid rafts, allowing for more rapid processing into Aβ (34). 
Alternatively, the loss of Fbxo2 may permit the continued existence of a pool of 
improperly complexed or folded APP which is not properly trafficked to the 
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surface and is preferentially retained in cortical neurons over hippocampal 
neurons. 
It is important to recognize that Fbxo2 may have functions beyond ERAD.  It is 
expressed throughout neurons including near synapses, far from the bulk of ER 
in neurons. The only known binding preference of Fbxo2 is for high mannose N-
linked glycans on glycoproteins, which traditionally are modified during passage 
through the secretory pathway, losing their high mannose status in the process 
(35). There is, however, precedence for cell surface expression of high mannose 
forms of another known Fbxo2 substrate, the NMDA receptor subunit GRIN1 
(36): all GRIN1 in neurons is susceptible to cleavage by EndoH, which cleaves 
high mannose N-linked glycans but not the complex glycans present on most 
glycoproteins after processing in the Golgi apparatus (37). Accordingly, even at 
the synaptic membrane GRIN1 remains a potential substrate for Fbxo2. The 
post-translational modifications to which APP is subjected are complex, and it 
remains uncertain whether immature (i.e. high mannose glycan-bearing) forms of 
APP exist in the cell beyond the ER.  If APP retains high mannose forms of N-
linked glycans on the cell surface, then Fbxo2 could play a role in regulating the 
endocytosis of APP through ubiquitination.  An effect on differential trafficking of 
APP - namely, the retention of APP in specific cellular compartments - has been 
attributed to Ubiquilin 1 (UBQLN1): polyubiquitination by UBQLN1 sequesters 
APP in the Golgi (38).  Given this observation, we examined the relative 
distribution of APP in ER and Golgi of neurons in Fbxo2 -/- and wild-type mice 
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and found no differences in the pattern of expression (data not shown). While 
these data suggest that altered sequestration of APP in the ER and Golgi does 
not occur, sequestration elsewhere in the secretory pathway or other vesicular 
bodies cannot be ruled out.
Our analysis of cultured hippocampal neurons suggests that neuronal 
connectivity is altered in the absence of Fbxo2. The marked changes in number 
and intensity of synaptic puncta in Fbxo2 knockout neurons are especially 
intriguing.  It is unlikely these data represent a universal increase in protein 
expression in the absence of Fbxo2, as the levels of two tested proteins that are 
not expected to interact with Fbxo2, BiP and Caspase-3, are unchanged.  
However, whether these additional synapses function normally remains 
unknown.  The presence of presynaptic terminals directly opposed to these 
postsynaptic markers suggests they are not “silent” synapses. But there may be 
other compensatory mechanisms by which these additional synapses are 
regulated.  Future studies will be required to examine the composition and 
contribution of these synapses. If these additional synaptic connections are 
indeed active, their activity may feed back onto APP processing. Intriguingly, both 
Aβ and sAPPα possess dose-dependent neuromodulatory functions (14).  
It is somewhat puzzling that cultured neurons from Fbxo2 -/- mice maintain more 
synapses in the presence of elevated Aβ, which has been shown to eliminate 
synapses (4).  It is not known how many substrates Fbxo2 has, but with regard to 
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synaptic dynamics two may be of particular importance: Beta Integrin 1 (16) and 
GRIN1 (36).  Beta Integrin 1 is a membrane receptor that supports cell adhesion 
and responds to cues from surrounding cells.  GRIN1 mediates the formation of 
NMDA receptors, which have profound effects on plasticity and structural change 
at the synapse. Both of these Fbxo2 substrates can significantly affect synapse 
formation, assembly, and maintenance.  Therefore, we consider it unlikely that all 
or even most of the synaptic changes in Fbxo2 null neurons and brain can be 
attributed to altered APP alone. 
In summary, our findings implicate Fbxo2 as a potentially important upstream 
regulator of key elements of neuronal health and function – APP processing and 
synaptic connectivity – that are also central to the pathogenesis of AD and 
perhaps other neurodegenerative diseases.
FIGURE LEGENDS
Figure 7. Fbxo2 expression leads to decreased levels of key glycoproteins in the 
amyloid pathway 
(a) APP levels are decreased in the presence of Fbxo2. HEK293 cells expressing 
full-length APP together with empty vector (EV) or vector encoding Fbxo2 were 
collected 48 hours after transfection. Lysates were examined by western blot with 
antibodies recognizing APP (22C11), Fbxo2, or GAPDH (upper panel). The 
mature, complex glycan-bearing form is denoted at ~130kD, and the immature, 
high mannose glycan-bearing form at ~110kD. Results of triplicate experiments 
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were quantified (lower panel).  (b) ADAM10 levels are decreased when Fbxo2 is 
co-expressed. Fbxo2 and ADAM10 were co-expressed as in panel a., and levels 
of ADAM10 were measured by anti-myc antibody (upper panel) and quantified 
(lower panel).  The mature form of ADAM10 is observed at ~60kD and the 
immature form at ~85kD. (c) Fbxo2 expression leads to decreased BACE1.  As in 
panel a., BACE1 and Fbxo2 were coexpressed and BACE1 levels were 
assessed by western blot using an anti-BACE1 antibody (upper panel) and 
quantified (lower panel). This antibody detects a single band of ~60kD 
corresponding to mature BACE1. Shown in lower panels are mean values from 
triplicate experiments.   Error Bars = S.E. *, p<0.05; ** p<0.01; **** p<0.0001; 
(unpaired t test).
Figure 8. Dysregulated APP processing and levels in Fbxo2 -/- neurons
(a) Increased APP in cultured Fbxo2 null neurons.  Cultured hippocampal 
neurons from p3 wild type and knockout pups, DIV 14, were lysed and APP 
levels measured by western blot. Representative results from four dishes per 
genotype are presented (left panel).  A significant increase in APP was observed 
and quantified (right panel); three replicates from different culture preparations 
were measured to control for potential prep-to-prep differences. (b) Loss of 
Fbxo2 results in a doubling of secreted APP cleavage products. Neuronal culture 
media was exchanged and then collected four days later and assessed by 
ELISA for secreted APP products.  Each measured product was approximately 
doubled in the knockout neurons, with the ratio of Aβ40 to Aβ42 remaining 
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unchanged (lower left panel). As in panel (a) representative quantification of 
quadruplicate samples from a single preparation are presented; three different 
preparations showed similar results. Error Bars S.E. *, *** p<0.001; **** p<0.0001 
(unpaired t test).  
Figure 9. Loss of Fbxo2 results in increased APP, altered APP localization and 
increased synaptic markers in cultured hippocampal neurons
(a) APP is increased and distributed differently in Fbxo2 null neurons. DIV 14 
hippocampal neurons were fixed, permeabilized, and immunostained for APP 
and synaptic markers.  Representative confocal images of wild-type and 
knockout neurons reveal increased overall APP compared to wild type controls, 
with a greater increase in dendritic than somatic immunoreactivity.  APP-
immunoreactive puncta (arrows in a, b) were observed to co-localize with the 
presynaptic marker Vglut (a) and with the postsynaptic marker Spinophilin (b).  
Levels of Vglut, Spinophilin, BiP, and PSD-95 (c) were also assessed and 
quantified, shown in (d). Caspase 3 (d) was measured by western blot as in 
Figure 8. Quantification of immunofluorescence was performed in six to eight 
neurons per genotype. For somatic and dendritic analysis, three to six dendritic 
segments of 100 um per neuron and six neurons per genotype were measured. 
Error Bars = S.E. ** p<0.01; *** p<0.001; (unpaired t test). Scale bar = 25um.
Figure 10. Increased levels of APP, but not Amyloid-β, in Fbxo2 -/- brain.
79
(a) The absence of Fbxo2 increases APP levels in whole brain. APP levels in 
brain lysates from wild-type and Fbxo2 null mice were assessed by western blot. 
Representative immunoblot results from three mice of each genotype at six 
months are shown (left panel).  APP levels were quantified and normalized at 
three time points, with an n of three animals per genotype at each time point 
(right panel).  Error Bars S.E. *, p<0.05 (unpaired t-test).  (b) and (c), APP 
cleavage products are not increased in whole brain of Fbxo2 null mice. ELISA 
assays for Aβ42 (b) and sAPPα (c) were performed on protein homogenates 
from whole brains of three mice per genotype at the indicated time points. (d) 
Levels of APP C-terminal fragments were measured in triplicate at three and six 
months by western blot.  Results for three month time point are presented (left 
panel) and results for both time points were quantified relative to loading control 
and total APP (right panel). (e,f) ADAM10 (e) and BACE1 (f) expression are not 
changed in the absence of Fbxo2.  Data shown represent quantification of three 
animals per genotype at three months.  Additional time points were examined 
and no differences were observed. 
Figure 11. Increased levels of APP in Fbxo2 -/- brain.
APP immunoreactivity is increased in the cortex of Fbxo2 null mice.  (a) Confocal 
microscopy shows increased levels of APP in Fbxo2 -/- mice (column a, lower 
row) compared to wild-type mice (upper row). From left to right, results from 
cortices are shown at 10x (a) and then in the denoted inset at 60x with a 2x 
optical zoom, at relatively lower (b) and higher brightness (c).  (d) A heat map at 
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the far right illustrates differences in pixel intensity. Scale bar = 50um (a) and 
20um (b).
Figure 12. Unchanged APP levels, but increased Amyloid-β, in Fbxo2 -/- 
hippocampus.
(a) Loss of Fbxo2 does not alter full length APP levels in the hippocampus. 
Hippocampi from wild-type and Fbxo2 null mice were dissected, lysed, and 
examined by western blot at three and six months of age.  Representative 
immunoblots from six months are shown (left panel) and quantified in three 
animals per genotype at three and six months (right panel).  (b) APP cleavage 
products are increased in the hippocampus of Fbxo2 null mice.  ELISAs show a 
significant increase in Aβ42 (b) at three months and suggest a nonstatistically 
significant increase in sAPPα (c). Results from three mice per genotype per time 
point were quantified. Error Bars = S.E. *, p<0.05 (unpaired t-test). (d) APP C-
terminal fragment levels were also measured in triplicate at three and six months 
by western blot.  Results from three month time point are shown (left panel) and 
quantified relative to loading control and total APP for both time points (right 
panel). (e) APP immunoreactivity is unaltered in the hippocampus of Fbxo2 null 
mice. Confocal microscopy reveals no difference in the levels of APP in Fbxo2 -/- 
mice (right panels) compared to wild-type mice (left panels). From left to right, 
results from the CA1 region of hippocampi are shown at 10x, and then in the 
denoted inset at 60x with a 2x optical zoom. 
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Figure 13. Decreased Surface Localization of APP in Hippocampi of Fbxo2 -/- 
mice
(a) Schematic of biotinylation procedure to assess surface APP levels in 
hippocampal slices.  Acute hippocampal slices were incubated with oxygenated 
artificial cerebrospinal fluid (ACSF) with or without biotin for 45 minutes, washed, 
blocked with lysine, lysed and homogenized, after which labeled surface proteins 
were affinity purified with streptavidin beads (see Experimental Procedures). (b) 
Surface levels of APP are reduced in the absence of Fbxo2.  Acute slices were 
processed as above and total and surface fractions were examined by western 
blot for APP, GAPDH, or the transferrin receptor as a control glycoprotein with 
surface expression.  Representative results from a single animal of each 
genotype are shown (left panel).  Three animals per genotype from three months 
of age were examined and the results quantified (right panel).  Error Bars = S.E. 
** p<0.01 (unpaired t test). 
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Figure 7. Fbxo2 expression leads to decreased levels of key glycoproteins in the 
amyloid pathway
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Figure 8. Dysregulated APP processing and levels in Fbxo2 -/- neurons
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Figure 9. Loss of Fbxo2 results in increased APP, altered APP localization and 
increased synaptic markers in cultured hippocampal neurons
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Figure 10. Increased levels of APP, but not Amyloid-β, in Fbxo2 -/- brain.
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Figure 11. Increased levels of APP in Fbxo2 -/- brain.
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Figure 12. Unchanged APP levels, but increased Amyloid-β, in Fbxo2 -/- 
hippocampus.
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Chapter Three: The Role of F-box Only Protein 2 (Fbxo2) in Synaptic 
Dynamics
ABSTRACT
NMDA receptors play an essential role in some forms of synaptic plasticity, 
learning, and memory. In addition, dysregulation of these receptors has been 
implicated in Alzheimer’s Disease, schizophrenia, and epilepsy. Previously, it was 
reported that NMDA receptor-mediated synaptic currents are reduced in cultured 
neurons in an activity-dependent manner that requires the ubiquitin ligase 
adaptor subunit, F-box Only Protein 2 (Fbxo2). Each NMDA receptor is formed 
as a heterotetramer of obligatory GluN1 and variable GluN2 subunits. Fbxo2 
facilitates the ubiquitination of GluN1 in cultured neurons, but the physiologic 
relevance of this regulation in vivo remains unclear. Whether Fbxo2 also can 
regulate GluN2 subunits in vivo and whether that control is subtype-specific are 
unknown. GluN2A and GluN2B are the most highly expressed GluN2 subunits in 
the mammalian hippocampus, a region strongly associated with memory and 
cognition. Although topologically similar, GluN2A and 2B confer different kinetic 
properties, downstream effects, and pharmacologic-sensitivities.  Here, we use 
an Fbxo2 knockout mouse to show that GluN1 and GluN2A, but not GluN2B, are 
substrates for Fbxo2 in vivo, and that the loss of Fbxo2 results in greater surface 
localization of GluN1.  Widespread increases in the synaptic markers PSD-95 
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and Vglut1 are also observed in the absence of Fbxo2.  We report that these 
synaptic changes do not manifest as electrophysiologic differences or alterations 
in dendritic spine density in Fbxo2 knockout mice, but result instead in a 
pronounced increase in axo-dendritic shaft synapses. Taken together, these 
findings suggest that Fbxo2 controls the abundance and localization of select 
NMDA receptor subunits in the brain and may influence synapse formation and 
maintenance. 
INTRODUCTION
NMDA receptors have profound effects on normal and pathologic processes in 
mammalian neurons (1).  The formation of spatial memories requires NMDA 
receptors (2), which also play a crucial part in the formation and retention of 
contextual fear memories (3).  Calcium conducted through NMDA receptors plays  
an important part in synaptic plasticity in the cortex and hippocampus.  This same 
calcium conductance, however, also links NMDA receptors to neuronal 
dysfunction and glutamate-induced excitotoxicity in stroke (4) and in 
neurodegenerative diseases such as Huntington’s Disease (5) and Alzheimer’s 
Disease (6-8). Dysregulation of NMDA receptors through pharmacologic 
antagonism in humans can result in impaired cognition and schizophrenia-like 
symptoms (9) and down-regulation of NMDA receptor subunit GluN1 by auto-
immune disease in humans induces both cognitive deficits and encephalitis, and 
in some patients, psychosis (10). How NMDA receptors are regulated under 
normal and pathological conditions remains an area of extensive investigation. 
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Fortunately, the effects of NMDA receptor dysregulation in humans are also 
partially observed in animal models, allowing for in-depth study of receptor 
structure and function in vivo. 
NMDA receptors are formed as heterotetramers containing both GluN1 and 
GluN2 subunits. GluN1 is necessary for receptor function and present in all 
NMDA receptors; it can be coupled with various GluN2 subunits, which regulate 
the kinetics and gating of receptor function (11).  During brain development, 
GluN2 subunits play a role in targeting receptors to synaptic or extra-synaptic 
sites at the plasma membrane, with GluN2A-containing receptors preferentially 
targeted to synaptic sites in adulthood and GluN2B-containing receptors targeted 
to extrasynaptic sites (12).  Activation of these two classes of NMDA receptors at 
their respective locations has profoundly different downstream effects on 
neuronal health and function: synaptic NMDA receptor activation supports 
neuroprotection and extrasynaptic activation promotes pro-apoptotic pathways 
(13). GluN2A and 2B-containing NMDA receptors are the most widely expressed 
types within the mammalian hippocampus(14), and as such mediate the majority 
of NMDA receptor-dependent functions associated with that brain region, 
including learning and memory (2,15).
As transmembrane glycoproteins, GluN1 and N2 subunits are synthesized in the 
endoplasmic reticulum (ER). Each subunit contains an endoplasmic reticulum 
retention signal, which becomes inactivated only when each subunit complexed 
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with its corresponding partner (16). GluN1 is produced at higher levels than 
GluN2, sufficient to create two pools: the first GluN1 pool forms a complex with 
GluN2 subunits and is trafficked to the plasma membrane, where its turnover 
half-life is roughly thirty hours (17).  The second pool is in excess of GluN2 levels 
and thus is not complexed with GluN2 subunits; it has been proposed to serve as 
a reserve pool available for times when rapid upregulation of NMDA receptors is 
required. This pool of unassembled GluN1 subunits is retained in the ER and is 
short-lived, lasting only three hours (17). 
A ubiquitin ligase adaptor subunit, the Fbox-containing protein Fbox2, has been 
shown to play an important role in the turnover of GluN1 in cultured hippocampal 
neurons (18). In a model of chemically induced long-term depression, over-
expression of a dominant-negative form of Fbxo2 prevented the reduction of 
NMDA-mediated currents (18). Fbxo2 is an E3 ligase substrate adaptor protein 
that preferentially binds high mannose glycans (19).  High-mannose glycans are 
added to the N-terminal region of GluN1 (18) in the ER but appear to remain on 
the subunit regardless of the location of GluN1 within the cell (17). 
The trafficking of NMDA receptors remains incompletely understood.  It has been 
suggested that complexed NMDA receptors bind to scaffolding proteins that are 
then trafficked to the plasma membrane, bypassing the normal Golgi apparatus 
(20,21).  NMDA receptor subunit mRNA has also been observed in dendrites, 
raising the possibility that NMDA receptor subunits can be locally synthesized in 
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distal neuronal processes (22).  Whether the same trafficking machinery is 
present for GluN subunits produced in dendrites is not known. Extensive post-
translational modifications to GluN subunits have been described for the 
modulation of NMDA receptor-mediated functions and trafficking, including 
multiple phosphorylation events (23). NMDA receptors are both able to influence 
and be influenced by synaptic activity, but many of the fundamental details of 
their governance and turnover remain unanswered. 
Here, we use cell-based model systems and Fbxo2 knockout mice to show that 
Fbxo2 is able to facilitate the degradation of NMDA receptor subunits, but does 
so selectively in the brain. Furthermore, we find that the loss of Fbxo2 affects 
subunit localization and significantly increases the formation of synaptic 
connections.
EXPERIMENTAL PROCEDURES
Animals - Fbxo2 -/- mice were generated via the targeted deletion of the first five 
of six exons encoding Fbxo2. Mice were backcrossed onto a C57BL/6J 
background strain.  Following examination, there were no reported abnormalities 
in brain size, weight, development, or adult gross brain structure. However, the 
cochleae of Fbxo2 knockout mice demonstrate degeneration (24).
DNA Constructs, HEK Cell Culture, and Cell Lysate Preparation – HEK-293 cell 
cultures were prepared and kept as previously described (24). Transfection of 
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constructs for GFP-Glun1, Glun2A, GluN2B (gifts from W. Rebeck, Georgetown 
University), or Fbxo2 (gift of K. Glenn, Univ. Iowa) was carried out using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s directions. 48 hours 
post-transfection, cells were lysed in hot denaturing buffer containing 2% SDS 
and 100mM DTT. Cell homogenates were boiled for five minutes, centrifuged, 
and loaded onto 4-15 or 4-20% gradient SDS-PAGE gels (Biorad). Cultured 
neurons were also processed in this manner for western blotting experiments.
Brain Extraction/Lysis – To prepare samples for immunoblotting, animals were 
anesthetized using ketamine/xylazine, followed by cardiac perfusion with pre-
warmed phosphate-buffered saline (PBS). Brains were dissected out following 
decapitation. As necessary, hippocampi were rapidly removed under a dissecting 
microscope. Using a dounce homogenizer, brain tissues were then homogenized 
in hot SDS (2%) lysis buffer with 100mM DTT, centrifuged, and boiled for five 
minutes. A protein quanitifcation kit (Macerey-Nagel, Duren, Germany) was used 
to measure the samples. Equal protein amounts were electrophoresed on 4-15 or 
4-20% SDS-PAGE gels. 
Western Blotting – Proteins were immunoblotted using antibodies against GluN1 
(Millipore) or its extracellular epitope (Alomone), GluN2A (Alomone), GluN2B 
(Alomone), GluR1 (Millipore), Fbxo2 (a gift from K. Glenn, Univ. Iowa, directed 
against the PEST domain of Fbxo2), Transferrin Receptor (Invitrogen), or 
GAPDH (Millipore).
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Deglycosylation of NMDA subunits – The glycosylation of GluN2A and GluN2B 
was assessed as previously described (17) with one modification: to increase 
substrate-to-enzyme ratio, GluN2 subunits were immunoprecipitated from 
separate hippocampal membrane fractions prior to incubation with glycolytic 
enzymes using antibodies directed against GluN2A (Invitrogen) or GluN2B 
(Invitrogen) conjugated to Protein G beads (Invitrogen). Enzymes were added 
directly to pelleted beads following 24-hour precipitation in reaction buffer.  
Reaction products were then examined by western blotting as described above.
Immunohistochemistry of frozen brain sections – Mice were processed as above, 
but were perfused with 4% paraformaldehyde in PBS following the PBS flush.  
Upon extraction, brains were post-fixed in 4% paraformaldehyde, rinsed in PBS, 
and cryopreserved.  After freezing, brains were cut into 12 micron sections and 
stored at -80 oC until use. Antibodies against GluN1 (Millipore), GluN2A 
(Invitrogen), PSD-95 (Abcam), Vglut1 (Millipore), VGAT(Millipore), and 
Spinophilin (Millipore) were visualized with AlexaFluor 488, 568 or 647 secondary 
antibodies (Invitrogen). Z-stack images were collected A-1 confocal microscope 
(Nikon) at the University of Michigan Microscopy and Image Analysis Laboratory 
through equal stack dimensions. Images were cropped using Photoshop CS3 
(Adobe). The portion of visual cortex (V1/V2) directly lateral and superior to 
region CA1 of the hippocampus along with CA1 were selected for imaging. Three 
male mice of each genotype at the six month time point were examined. 
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Immuofluorescent intensities were analyzed using Fiji Image J software.
Hippocampal Neuron Culture and Immunofluorescence – Hippocampal neurons 
cultured from 3 day postnatal male and female pups, plated at 80,000 cells per 
dish onto glass-bottom dishes (Mattek), and were maintained and processed for 
immunocytochemistry as previously described (25,26). Neurons were stained or 
harvested for western blotting at 14 days in vitro (DIV14). Antibodies against 
GluN1 (Millipore), GluN2A (Alomone), GluN2B (Alomone), PSD-95 (Abcam), 
Vglut1 (Millipore), VGAT(Millipore), Spinophilin (Millipore), were visualized using 
AlexaFluor 488, 568 or 647 secondary antibodies (Invitrogen). Confocal images 
were obtained using an A-1 confocal microscope (Nikon) at the University of 
Michigan Microscopy and Image Analysis Laboratory.
Proteolysis of Surface Proteins – The surface expression of GluN1 in 
hippocampal neuron cultures at DIV14 was assessed as previously described 
(27,28). Briefly, neurons were incubated with or without Chymotrypsin (Sigma) for 
10 minutes at 37 oC and then lysed and analyzed by western blot. 
Cell-Surface ELISA – Surface levels of GluN1 among cultured neurons at DIV14 
in the presence or absence of 50 µM Bicuculine (Sigma) for 48 hours was 
accomplished using a previously described method (29) and an antibody directed 
against the extracellular loop of GluN1 (Alomone). For each condition in these 
experiments, 320,000 neurons were plated into each well of clear-bottom six-well 
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dishes (Corning) and maintained as above. 
Acute Slice Biotinylation – Comparison of total protein amounts to surface levels 
was accomplished as previously described (26,30). In brief, male mice were 
anesthetized and their hippocampi rapidly removed in ice cold, oxygenated 
artificial cerebrospinal fluid (ACSF). 350 µm hippocampal slices were cut using a 
MacIlwain Tissue Chopper, and alternate sections from both hippocampi were 
incubated in cold, oxygenated ACSF in the presence or absence of EZ-Link 
Sulfo-NHS-LC-biotin (Pierce) for 45 minutes. Slices were then washed in ACSF 
and incubated briefly in lysine to quench any unbound biotin. Slices were washed 
again in ACSF, and the slices incubated without biotin were processed for 
western blotting as described above and retained at -80 oC as the “total” fraction. 
Biotinlyated slices were lysed in precipitation buffer containing 1% TX-100, 0.1% 
SDS, 1 mM EDTA, 50 mM NaCl, 20 mM Tris, pH 7.5, with protease inhibitors 
(Roche) in a glass homogenizer. Streptavidin Resin (Pierce) was then added and 
biotinylated proteins were then precipitated overnight at 4 oC with rotation. The 
resultant precipitates were centrifuged to separate the resin from the 
supernatant, and the resin was resuspended in SDS (2%) lysis buffer with 
100mM DTT and boiled. This “surface” fraction was kept at -80 oC until being 
immunoblotted. Lanes containing 25 µg and 2.5 µg of “total” protein were run on 
the same gel as 2.5 µg of “surface” protein.
Preparation of Acute Hippocampal Slices for Electrophysiology – Animals were 
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placed under deep halothane anesthesia before decapitation. Coronal sections 
(300 µm) were cut on a VT1000S vibratome (Leica) in ice cold sucrose cutting 
solution saturated with 95% O2/5% CO2 containing (in mM): 206 sucrose, 26 
NaHCO3, 2.8 KCl, 1.25 NaH2PO4, 1 CaCl2, 3 MgCl2, 0.4 ascorbic acid, and 25 
d-glucose. Hippocampal slices were then allowed to recover for at least 1 hour at 
room temperature in a holding chamber containing artificial cerebrospinal fluid 
(ACSF) saturated with 95% O2/5% CO2 containing (in mM): 125 NaCl, 25 
NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 0.4 ascorbic acid, and 25 
d-glucose. All recordings were made in a submerged chamber perfused 
continuously with oxygenated ACSF at elevated temperature (30-32°C).
Electrophysiology of Synaptic Transmission in the Hippocampus – Extracellular 
recordings of field excitatory postsynaptic potentials (fEPSP) were made in the 
stratum radiatum of CA1 with a differential amplifier (DP-301, Warner 
Instruments) using borosilicate glass (Sutter Instruments) to make pipettes with a 
P-97 Flaming-Brown pipette puller (Sutter Instruments) with a tip resistance of ~1 
MΩ filled with ACSF. Recordings were digitized using an Axon Instruments 
1440A Digidata A/D converter and stored on a Dell desktop computer running 
pClamp 10.2 (Axon Instruments). Field EPSPs were evoked by stimulating the 
Schaffer collateral afferent fibers with bipolar platinum electrodes (square pulse, 
100 µs in duration). An input/output curve was first generated in ACSF by 
delivering test stimuli every 10 s with increasing stimulus intensity (from 0 to 0.5 
mA). To isolate the NMDA-mediated component of the fEPSP response, ACSF 
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containing 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 50 µM; Sigma-Aldrich) 
was then washed into the bath while continuously monitoring the fEPSP 
amplitude at the half-max stimulus intensity (once every 30 s). As expected, the 
amplitude of the fEPSP significantly decreased in the presence of CNQX; when 
there was no further decrease in fEPSP amplitude, another input/output curve 
was generated (as above) in the presence of CNQX. The amplitude of the fiber 
volley and the fEPSP were quantified relative to baseline. Statistical comparisons 
between conditions were made using a repeated-measures ANOVA. 
Electrophysiology of Miniature Synaptic Currents and Long-Term Potentiation – 
ACSF-filled glass electrodes (resistance <1 MΩ) were positioned in the stratum 
radiatum of area CA1 for extracellular recording.  Synaptic responses were 
evoked by stimulating Schaffer collaterals with 0.1 ms pulses with a bipolar 
tungsten electrode (WPI Inc., Sarasota, FL) once every 15 s. The stimulation 
intensity was systematically increased to determine the maximal field excitatory 
post-synaptic potential (fEPSP) slope and then adjusted to yield 40-60% of the 
maximal (fEPSP) slope. Experiments with maximal fEPSPs of less than 0.5 mV 
or with substantial changes in the fiber volley were rejected. After recording of a 
stable baseline for 15 min, LTP was induced by one 1 s/100Hz stimulus train.
 Field EPSPs were recorded (AxoClamp 2B amplifier, Axon Instruments, Foster 
City, CA), filtered at 1 kHz, digitized at 10 kHz (Axon Digidata 1200), and stored 
for off-line analysis (Clampfit 9). Initial slopes of fEPSPs were expressed as 
percentages of baseline averages. In summary graphs, each point represents the 
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average of 4 consecutive responses. The time-matched, normalized data were 
averaged across experiments and expressed as means±SEM. For statistical 
analysis, the last 5 min in each measurement were average and normalized to 
the average of the baseline preceding LTP induction before comparison with the 
corresponding control values.
 Whole-cell recordings from pyramidal neurons in CA1 with a holding potential at 
-70 mV provided mEPSCs. Patch pipettes (3~6 MΩ), were pulled from KG-33 
glass capillaries (1.1 mm I.D., 1.7 mm O.D., Garner Glass Company, Claremont, 
CA) on a Flaming-Brown electrode puller (P-97, Sutter Instruments Co., Novato, 
CA) and filled with internal solution (in mM: 125 K-Gluconate, 20 KCl, 10 NaCl, 2 
Mg-ATP, 0.3 Na-GTP, 2.5 QX314, 10 PIPES, 0.2 EGTA, pH 7.3 adjusted with 
KOH). Slices were perfused with ACSF. GABAA receptor currents were blocked 
with 50 µM picrotoxin (Sigma), NMDAR currents with 10 µM APV (Sigma), and 
Na+ channel currents with 1 µM tetrodotoxin (TTX, Sigma). Recordings were 
made using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA), 
filtered at 1 kHz, digitized at 10 kHz via an Axon Digidata 1322A, and stored for 
off-line analysis.
Dendritic Spine Labeling – Acute hippocampal slices were prepared as above, 
and then immediately fixed using 2% paraformaldehyde in PBS (31). Following 
fixation, slices were rinsed and labeled with DiI (Invitrogen) for 24 hours. They 
were then mounted using Prolong Gold antifade reagent (Invitrogen) and 
visualized as above.  Z-stack images were reconstructed and dendrites were 
104
modeled in a semi-automated manner using Imaris software as previously 
described (32). Dendritic segments from stratum radiatum of four male mice per 
genotype were analyzed, totaling 60 dendritic segments per genotype. Data were 
compiled using Excel (Microsoft) and analyzed using Prism 6 software 
(GraphPad).
Transmission Electron Microscopy – Mice were anesthetized and flushed as 
above, then fixed with 2.5% Glutaraldehyde in 0.1 M Sorensen’s buffer.  
Hippocampi were then dissected out under a dissecting scope and then 
immersion fixed overnight at four degrees. Hippocampi were then trimmed to 
1mm x 1mm blocks, rinsed in Sorensen’s buffer, then post-fixed for one hour in 
one percent osmium tetroxide in the same buffer, and rinsed again in fresh 
Sorensen’s buffer.  The tissue was then dehydrated in ascending concentrations 
of ethanol, transitioned through propylene oxide, and embedded in Epon epoxy 
resin.  Semi-thin sections were stained with toluidine blue for tissue identification.  
Selected regions of interest were ultra-thin sectioned 70 nm in thickness, 
mounted on copper mesh grids (Ted Pella), and post stained with uranyl acetate 
and lead citrate. Sections were imaged using a Philips CM100 electron 
microscope at 60 KV.  Images were recorded digitally using a Hamamatsu 
ORCA-HR digital camera system, operated using AMT software (Advanced 
Microscopy Techniques Corp., Danvers, MA). 4 male animals per genotype were 
examined, totaling 500µm of dendritic segments from stratum radiatum of 
hippocampus. Shaft synapses were counted by three separate lab members, 
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blind to genotype, and there was no statistically significant difference between 
their counts. 
Quantification and Statistical Analysis – Immunoblot results were scanned using 
Adobe Photoshop and analyzed using ImageJ software. Prism 6 software 
(GraphPad) was used for statistical analysis and to make graphs. 
Immunofluorescence data was analyzed using ImageJ as previously described 
(26,33).
RESULTS
Fbxo2 has been shown to facilitate the degradation of the NMDA receptor 
subunits GluN1 in cultured neurons (18) and GluN2A  in transfected non-
neuronal cells (34).  To investigate whether Fbxo2 similarly participates in the 
clearance of the NMDA receptor subunit GluN2B, we transiently expressed 
plasmids encoding these proteins in HEK293 cells together with either FLAG-
tagged Fbxo2 or empty vector (Fig 14). Whereas levels of GluN1 and GluN2A 
were markedly reduced when co-expressed with Fbxo2 (Fig 14, a), consistent 
with prior studies (18,34), GluN2B levels were decreased by approximately 50% 
(Fig 14, c).  
As NMDA receptors are nervous-system-specific and Fbxo2 is brain-enriched, 
we sought to move beyond the over-expression of neuronal proteins in non-
neuronal cells to examine the physiological significance of Fbxo2 for GluN1, 
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N2A, and N2B in vivo in the nervous system. Utilizing Fbxo2 knockout mice 
generated in our lab (24), we observed that GluN1 levels are almost 300% of 
those in wild-type mice at three months of age, and 150-200% at six and nine 
months of age (Fig 15, a).  GluN2A levels are also consistently increased in the 
absence of Fbxo2, at around 150% of wild-type controls from three through nine 
months of age (Fig 15, b).  In contrast, Fbxo2 does not appear to regulate the 
levels of GluN2B in vivo, which remain unchanged in Fbxo2 knockout brains for 
all ages examined (Fig 15, c). 
As a ubiquitin ligase subunit that binds substrates, Fbxo2 preferentially targets 
glycoproteins that contain high-mannose glycans (19).  High mannose N-linked 
oligosaccharides on glycoproteins are typically processed to a complex (not high 
mannose) form as a protein transits through the Golgi apparatus (35).  However, 
it has been suggested that NMDA receptor subunits are not trafficked through 
this canonical system, instead making use of alternative methods for transport 
from the endoplasmic reticulum to the cell surface (21).  Bypassing the Golgi 
would allow the high-mannose glycans placed on NMDA receptor subunits in the 
ER to be retained even as these receptors arrive at the cell surface. As a result, 
NMDA receptor subunits would remain sensitive to Endoglycosidase H (Endo H), 
which selectively cleaves high-mannose glycans on glycoproteins.  This has 
been previously shown to be the case for GluN1 (17), raising two intriguing 
possibilities: 1) that the differential regulation of GluN2A and GluN2B observed in 
the Fbxo2 knockout brain reflects a difference in the retention of high-mannose 
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glycans on different NMDA receptor subunits; and 2) that even at the synapse, 
NMDA receptor subunits remain potential candidates for regulation by Fbxo2.  
To investigate the first of these, it was critical to determine whether these 
subunits are similarly Endo H sensitive. To do so, hippocampi were removed from 
six month old mice, and a membrane fraction was prepared.  GluN2A and 
GluN2B were then immunoprecipitated from separate samples and the resultant 
product was treated with Endo H, PNGaseF (which cleaves all N-linked glycans), 
or left untreated.  These proteins were then examined by western blot.  We 
observed similar Endo H sensitivity, for both GluN2A and 2B, evident as a 
decrease in molecular weight (Fig 15, d and e).  The entire population of both 
receptor subunits remained Endo H sensitive at one or more oligosaccharides, 
suggesting that all GluN2A and 2B subunits associated with neuronal 
membranes retain the requisite high-mannose glycans for recognition by Fbxo2.  
Both subunits showed further reduction in molecular weight when treated with 
PNGaseF, suggesting the presence of additional, complex glycans. Given the 
abundance of post-translational modifications reported for GluN2 receptor 
subunits, GluN2B levels are likely governed by other mechanisms independent of 
Fbxo2. The E3 ligase Mind bomb-2, for example, has previously been shown to 
regulate GluN2B levels in a phosphorylation-dependent manner (36).
To explore the possibility of whether Fbxo2 plays a role in determining the NMDA 
receptor content at synapses, we first sought to visualize the distribution of 
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increased GluN1 and GluN2A in Fbxo2 knockout mice. To do so, we performed 
confocal immunofluorescence microscopy on six-month old mouse brain. In 
cortex (Fig 16, a) and CA1 of hippocampus (Fig 16, b), we observed increased 
amounts of GluN1 both in cell bodies and throughout the neuropil. Elevated 
GluN2A appeared predominantly throughout the neuropil.  We did not observe 
subregional differences between cortex and hippocampus in the extent of these 
increases. 
Increased levels of NMDA receptor subunits could represent an increase in 
receptor levels at the plasma membrane or the retention of subunits in 
intracellular pools. Previously, pharmacologic elevation of NMDA receptor subunit 
levels was shown to increase NMDA synaptic currents and enhance postsynaptic 
plasticity (37). Over-expression of GluN2A and GluN2B has also been shown to 
cause the formation of increased synaptic NMDA receptors (38,39), but whether 
the robust increase in endogenous subunit proteins observed in the absence of 
Fbxo2 would yield similar results remains unclear. To address whether these 
increased endogenous NMDAR subunit proteins were present on the cell surface 
and at synapses, several lines of investigation were used.  First, we 
hypothesized that a substantial increase in NMDAR receptor content at synapses 
would involve a concomitant increase in the extent of post-synaptic architecture 
necessary to stabilize those receptors. PSD-95 has been shown to anchor 
GluN2A-containing receptors at synaptic sites on the cell surface (40).   
Additionally, presynaptic markers might also increase as a response to additional 
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post-synaptic content.  We previously reported an increase in PSD-95 and Vglut1 
in cultured hippocampal neurons from mice lacking Fbxo2 (26), and therefore 
inquired whether this same phenomenon was present in vivo.  Using confocal 
immunofluorescence microscopy of six-month old mice, we examined the CA1 
region of the hippocampus. In Fbxo2 knockout mice, PSD-95 and Vglut1 levels 
were 175-200% of wild-type controls (Fig 17, a and b).  We did not, however, 
observe a significant difference in the levels of spinophilin, a protein enriched in 
dendritic spines, nor in the levels of the vesicular GABA transporter (VGAT) 
present at synapses of inhibitory interneurons.  Despite the increase in pre- and 
post-synaptic markers, we also did not observe a difference in the levels of the 
AMPA receptor subunit GluR-1 (Fig 17, c and d).  NMDA receptor function is 
voltage-dependent with AMPA receptors playing the role of a depolarizing agent 
for the postsynaptic cell. Several substrates identified for Fbxo2 have been 
implicated in synapse formation and stability, including Beta Integrin 1 (19), the 
Amyloid Precursor Protein (26,41), and NMDA receptors themselves (42). With 
such heightened levels, colocalization of GluN immunoreactivity with that of 
synaptic markers appeared to be extensive at this scale.  However, as the 
question of GluN1‘s surface and synaptic localization was central to 
understanding the consequences of Fbxo2’s absence, we elected to more 
carefully examine protein distribution and colocalization with greater detail by 
using cultured hippocampal neurons.  Cultured neurons provide a practical 
means to biochemically assess the handling of proteins within living neurons and 
greater visual resolution of protein localization than in vivo studies. 
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To more effectively examine the distribution of NMDA receptors and their surface 
presentation in neurons, we cultured hippocampal neurons from P2 wild-type and 
knockout pups.  At DIV 14, these neurons showed similar differences in GluN1 
and N2A levels, but a decrease in GluN2B levels (Fig 18, a).  As previously 
reported, Fbxo2 is expressed as early as DIV 3 in this system (26).  
Fbxo2 has been described previously for its role in clearing proteins through ER-
associated degradation (ERAD) (34), and not for regulating the surface levels of 
substrate proteins. However, the work of Bredt. et al demonstrated the 
persistence of NMDA currents when Fbxo2 function was repressed (18) - 
suggesting that the NMDA receptors no longer being handled by Fbxo2 were 
retained on the cell surface. To elucidate this point, we next sought to address 
whether the increase in GluN1 levels in our Fbxo2 knockout neurons 
corresponded to subunits expressed on the neuronal cell surface or retained 
intracellularly in the absence of Fbxo2.  Exogenously applied chymotrypsin will 
cleave the extracellular domain of transmembrane proteins present on the 
surface of neurons.  Using this technique, we were able to measure by western 
blot the amount of GluN1 in untreated cultures versus the amount remaining after 
chymotrypsin cleavage, with the chymotrypsin-resistant fraction representing 
GluN1 not present on the cell surface. In treated cultures, after chymotrypsin 
treatment a lower molecular weight GluN1 band of ~ 50kD was observed, which 
presumably represents the intracellular portion of the receptor left following 
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surface cleavage.  Despite an increase in GluN1 to nearly 150% that of wild-type 
controls, in Fbxo2 knockout neurons only ~10% of GluN1 is chymotrypsin-
resistant, significantly less than in wild-type controls (Fig 18, b). These results 
suggest that nearly all the increased GluN1 present in the absence of Fbxo2 
reaches the cell surface. 
We next inquired whether we could observe changes in the ability of Fbxo2 
knockout neurons to remove GluN1 from the cell surface. In their studies, Bredt 
et al. drove the activity-dependent down-regulation of synaptic NMDA receptors 
by using a model of long-term depression (LTD) evoked by bicuculline treatment 
(18). Exposure to bicuculline for 48 hours has been shown to cause the 
internalization of NMDA receptors. Using an antibody against the extracellular 
loop of GluN1 yielded weak signal, so we used larger cultures in a cell-surface-
based-ELISA reporter assay to measure the amount of internalization in treated 
versus untreated cultures.  Whereas approximately half of the surface receptors 
in wild-type neurons were removed following bicuculline treatment, approximately 
all of the surface receptors in knockout neurons remained on the surface, as 
evident by equal surface immunoreactivity between treated and untreated 
cultures of Fbxo2 knockout neurons (Fig 18, c).  These results are consistent with 
previously reported observations, and suggest a persistence of NMDA receptors 
at the cell surface following loss or disruption of Fbxo2.  
The finding that increased GluN1 is present on the cell surface does not reveal 
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whether that surface GluN1 is present at synapses. To elucidate this question, 
the colocalization of GluN1 and synaptic markers was observed using confocal 
immunofluorescence microscopy. GluN1 levels were increased throughout Fbxo2 
knockout neurons, most notably at numerous, large GluN1-positive puncta in 
dendrites (Figure 19, a, arrows).  These puncta colocalize with the synaptic 
marker Vglut1 (Figure 19, a), suggesting that increased receptor levels are 
present at synapses.  In accordance with our western blot data, GluN2A levels 
are increased in cultured neurons and GluN2B levels appear decreased (Fig 19, 
b and c).
Having observed greater surface localization of GluN1 in vitro, we sought to 
determine whether this change also occurred in vivo.  Neither chymotrypsin 
cleavage nor cell-surface-based-ELISA is compatible with in vivo studies, so 
instead we employed surface biotinylation of acute hippocampal slices, 
previously used to measure surface proteins in vivo (26,30).  We focused on the 
hippocampus because of its functional importance and because it is a discrete 
subcortical region that can be readily and reproducibly isolated by dissection, 
adding to its value as a model system for these studies.  Following biotinylation 
and immunoprecipitation, Fbxo2 knockout mice showed a marked increase in 
surface GluN1 and GluN2A: approximately 200% of that observed in wild-type 
controls (Fig 20).  By contrast, levels of the Transferrin Receptor, which was used 
as a loading control for the surface fraction were not altered in Fbxo2 knockout 
mice. 
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With the greater levels of cell surface NMDA receptor subunits and increased 
synaptic marker proteins in Fbxo2 knockout mice, we predicted that NMDA-
mediated current in acute hippocampal slices would also be increased in 
knockout mice. However, field recordings from region CA1 of hippocampus of 3-6 
month old Fbxo2 knockout mice did not reveal any difference in basal 
transmission (Figure 21, a, filled circles) or in NMDA-mediated current recorded 
in the presence of AMPA-receptor blocker CNQX (Fig 21, a, open circles).  
Moreover, no difference was observed in the size of fiber volleys evoked for each 
genotype (Fig 21, b), and plotting the fiber volley data against the field excitatory 
post-synaptic potentials (EPSPs) revealed no difference between genotypes 
(figure 21, c).   The frequency, amplitude, and decay of spontaneous miniature 
excitatory post-synaptic currents (EPSCs) did not differ between genotype (Fig 
22, b, c, d).  Long-term potentiation (LTP) evoked by 100Hz stimulation was also 
equal in amplitude and persistence out to 60 min for mice with and without Fbxo2 
(Fig 22, e and f). 
The output measured in each of these experiments hinges upon functional 
receptors on the post-synapse. Our findings are consistent with the interpretation 
that the increased NMDA receptors of Fbxo2 knockout mice are not functional 
and do not participate in synaptic transmission.  The lack of a concomitant 
increase in GluR1 levels (reported in Fig. 17, c) suggests one mechanism (the 
absence of sufficient AMPA receptors) by which additional synapses in Fbxo2 
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knockout mice are kept silent.  However, these recordings were performed in low 
or zero Mg2+, a non-physiologic condition that circumvents the voltage-
dependent block of NMDA receptors.  Still, numerous other potential 
mechanisms exist for the modulation of NMDA receptor activity including 
regulation by Protein Kinase A (43), Protein Kinase C (44,45), and Src kinase 
(46), among many others. 
As a potential confounding factor to the interpretation of these studies, we 
discovered that following incubation in ACSF for several hours, the difference in 
GluN1 levels between wild-type and Fbxo2 knockout mice is ameliorated (Fig 23, 
a).  This is an important observation because slices used for electrophysiology 
experiments are cut and typically allowed to recover for one hour, then recorded 
from over a period of hours, such that slices may remain incubated in ACSF 
anywhere from 1 to 5 hours following recovery. To address the timing of this 
equalizing phenomenon with GluN1, we re-examined those slices used for the 
“total” fraction in our biotinylation experiments, which were similarly cut but were 
incubated for only one hour prior to lysis.  These slices show a consistent 
difference in GluN1 between genotypes (Fig 23, b), suggesting that it takes 
several hours for the equilibration of NMDA receptor subunit protein content to 
occur.  Importantly, no apparent difference was observed between slices 
recorded at the earliest point in each session and those recorded hours later, 
further suggesting that the increased GluN1 content of Fbxo2 knockout mice is 
not electrophysiologically active.
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Given the absence of obvious electrophysiological consequences of increased 
GluN1 and N2A in Fbxo2 knockout brain, we recognized that it was critically 
important to assess the morphological impact of increased NMDA receptor 
subunits, as well as increased pre- and post-synaptic marker proteins, on the 
structures essential for synaptic transmission.  To do so, we cut thick sections of 
region CA1 which were then fixed, labeled with DiI, and imaged by confocal 
microscopy.  Dendrites were then reconstructed in three-dimensions and spines 
were measured and counted in a semi-automated manner (example images Fig 
24, a and b).  Using this method, we observed no difference in the density of 
dendritic spines (Fig 24, c).  A significant reduction in spine length was observed, 
however, with spines in Fbxo2 knockout hippocampus reaching only 78% of the 
length seen in wild-type neurons (Fig 24, c).  Much smaller, but statistically 
significant differences were observed in the diameter of the head and neck of 
spines: on average, knockout spine heads were 5% larger, and the necks 13% 
thinner (Fig 24, c).  Overall, there was minimal difference in spine size and shape 
and no difference in density. Thus, the extensive changes in protein content 
evident in Fbxo2 knockout mice do not appear to impair other mechanisms 
regulating spinogenesis and spine density.
With no apparent change in spine density or electrophysiological parameters in 
Fbxo2 knockout mice, the presence of increased synaptic markers would seem 
paradoxical.  In an effort to explain this discrepancy, we examined the 
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ultrastructure of pyramidal cells in region CA1 by Transmission Electron 
Microscopy (TEM).  At this greatly increased resolution, we observed a striking 
and significant difference in the architecture of dendrites from neurons lacking 
Fbxo2: a marked increase in axo-dendritic shaft synapses (Fig 25, a-f) in Fbxo2 
knockout hippocampus.  These synapses demonstrated an electron-dense 
postsynaptic density, and were opposed to pre-synaptic terminals with apparent 
vesicles (Fig 25, insets b, d, and e). While these structures are rarely seen in 
wild-type dendrites (Fig 25, h and inset i)(47,48), we identified shaft synapses 
decorating Fbxo2 knockout neurons at a density approaching that of spinous 
synapses (~50-90%; Fig 25, g). Shaft synapses were found both adjacent to 
dendritic spines (Fig 25, a and b) and at a distance from them (Fig 25, c-f). A 
subset of these structures appeared with a discontinuous (or perforated) 
postsynaptic density (Fig 25, e and d) but were still counted as a single synapse 
for the purposes of quantification. Taken together, these results suggest that the 




Here we have identified a role for Fbxo2 in regulating the levels of specific 
NMDA receptor subunits in vivo, namely GluN1 and GluN2A.  We have found 
that the increased levels of these subunits in mice lacking Fbxo2 are 
accompanied by an enhancement of surface and synaptic localization. These 
changes were accompanied by elevated amounts of synaptic marker proteins, 
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but no change to the density of dendritic spines. These additional synapses did 
not appear to affect synaptic transmission, and through electron microscopy, 
were found localized along dendritic shafts. 
The necessity of the presence on the substrate of high-mannose glycans in order 
for Fbxo2 to interact with and regulate it has been established previously for 
GluN1 (18) and additional proteins (19). But our findings with GluN2A and N2B 
suggest that in the hippocampus, the presence of these glycans is not the only 
factor determining regulation by Fbxo2. In Fbxo2 knockout mice, we report 
increased levels of both pre- and post-synaptic markers but this increase is not 
accompanied by a change in spine density or electrophysiological properties in 
slice culture, suggesting that the increased synaptic markers may reflect silent 
synapses. Using fixed tissue, we provide evidence of heightened numbers of 
axo-dendritic excitatory shaft synapses, as well as greater surface localization of 
GluN1 and N2A within the hippocampus of knockout mice.  
Many forms of neuronal plasticity require the degradation of existing synaptic 
proteins (49,50), while also placing demands on local machinery for new protein 
synthesis (51,52). Protein quality control pathways exist to ensure these 
demands are met with the appropriate complement of properly synthesized and 
correctly assembled proteins. Proteins synthesized in dendrites are processed in 
specialized ER near dendritic spines (53). With limited evidence for the presence 
of Golgi apparatus at these local sites (54), it is intriguing to speculate that GluN 
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subunits may not be the only synaptic proteins still bearing high-mannose 
glycans. As a brain-enriched ubiquitin ligase substrate adaptor protein linked to 
ERAD (34), Fbxo2 is an appealing target for studying the role of protein quality 
control pathways in responding to the unique proteostatic needs of neurons, 
especially given its localization at synaptic sites and throughout the neuronal 
cytoplasm (18). Intriguingly, Fbxo2 levels are reportedly decreased in Alzheimer’s 
Disease (AD) patient brain tissue (55).  Fbxo2 has already been linked to the 
regulation of the Amyloid Precursor Protein, the central causative protein in AD 
(26), and we now link it to a second factor proposed to play a role AD, the 
dysregulation of NMDA receptors. For these reasons, further studies will be 
needed to fully address the contribution of Fbxo2 reduction in AD pathogenesis. 
In our present studies, the observed increase in surface localization of GluN1 
and N2A in Fbxo2 -/- mice is an effect beyond the straightforward elevation of 
substrate protein levels. This effect more likely results from one of two scenarios. 
First, Fbxo2 could affect the endocytosis of receptors through an ubiquitin-
dependent signal on NMDA receptors; indeed such a mechanism has been 
described elsewhere for EGFR receptors (56,57). Alternatively, downstream of 
endocytosis Fbxo2 may play a key role in determining receptor fate.  Receptors 
on the surface are regularly endocytosed and either recycled back to the surface 
or targeted for degradation (58). A role for Fbxo2 in this triage pathway is 
supported by the presence of high-mannose glycans on all membrane-
associated GluN2 subunits, suggesting their continued capacity to interact with 
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Fbxo2. The fact that Fbxo2, an intracellular protein, binds substrates through 
their high mannose glycans, which reside on the extracellular face of surface 
glycoproteins, argues against a direct role for Fbxo2 in regulating endocytosis 
itself. The high-mannose glycans on GluN1, GluN2A and other synaptic 
glycoproteins targeted by Fbxo2 should remain inaccessible to Fbxo2 even after 
the initial steps of endocytosis.   Thus we suggest that internalization of NMDAR 
must precede ubiquitination of GluN subunits by Fbxo2, much like the activity-
dependent ubiquitination of GluA2 requires clathrin-mediated endocytosis of the 
receptor before ubiquitination can occur (59). Upon endocytosis, these formerly 
extracellular glycans would reside within endosomes, but a translocation 
apparatus analogous to the translocation apparatus that mediates ERAD could 
facilitate the presentation of N-terminal glycans to intracellular Fbxo2.  Evidence 
for such an apparatus includes the identification of Sec61B, a core component of 
the ER translocation machinery, on endosomes (60,61). Alternatively, delivery of 
substrates to dendritic ER, followed by Sec61B-mediated presentation to the 
cytosol, remains a possibility. In this scenario, the kinetics of NMDA receptor 
recycling would remain the same whether Fbxo2 is present or not, but knockout 
neurons would develop an increased amount of receptors on the surface for want 
of counterbalancing degradation. The method of chemical LTD employed in our 
studies and used elsewhere requires a lengthy treatment, on the order of 48 
hours, making it difficult to interpret whether endocytosis of NMDA receptors itself 
is impaired. More rapid internalization protocols could help to elucidate whether 
these receptors are properly internalized. We did attempt additional 
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pharmacologic treatments on shorter time scales but they did not elicit robust and 
consistent internalization of NMDA receptors in wild-type control neurons. Further 
studies employing subunits with pH-sensitive fluorescent tags could shed light on  
whether the kinetics of endo- and exocytosis of NMDA receptor subunits remains 
normal following the loss of Fbxo2. 
If the levels of GluN1 and GluN2A depend on Fbxo2-mediated ubiquitination and 
subsequent degradation, it is nevertheless likely that many other mechanisms 
also contribute to the regulation of NMDAR levels and activity at the synapse. 
The  contribution of those subunits to synaptic transmission and downstream 
NMDA receptor-mediated signaling in Fbxo2 knockout brains when joined as 
receptors is likely determined in the context of, and under the control of, 
numerous complex mechanisms governing homeostatic plasticity, in which Fbxo2 
likely has little, if any, direct role. That we observe no change in spine density and 
no proportional change in head diameter suggest that in the absence of Fbxo2 
the mechanisms responsible for regulating the morphology of spinous synapses 
continue to function (62-64). The loss of Fbxo2 does not interfere with these 
mechanisms, even though Fbxo2 does localize to spines (18). 
Our findings raise an intriguing question: where, if not at spinous synapses, do 
these additional NMDA receptors in Fbxo2 knockout mice reside? The plasma 
membrane is populated with pools of receptors that are believed to function as a 
reserve stock for rapid changes in receptor content at synapses (65-68).  
121
Upwards of 65% of synaptic NMDA receptors are mobile and participate in 
exchange with extrasynaptic pools (69). It is unclear, however, what regulates the 
size of these reserve pools. GluN2A-containing receptors are preferentially 
targeted to synapses, but are also found in these reserve pools and can be 
laterally trafficked into synapses as needed (69). Because the amount of NMDA 
receptors at spinous synapses is tightly regulated and no alteration in synaptic 
transmission was observed, it stands to reason that the increased steady-state 
levels and surface localization of GluN1 and N2A in Fbxo2 knockout mice 
represent an increase in the reserve pool of NMDA receptors. 
On its own, however, this model of an increased reserve pool does not account 
for the significant increase we observe in synaptic markers.  Previous studies 
involving the over-expression of GluN subunits have reported an increase in 
NMDA-mediated synaptic currents (38,39), but have not commented on whether 
these currents were accompanied by additional synaptic markers, as observed 
here in the absence of Fbxo2. The NMDA receptor interacts with PSD-95, which 
has been suggested to serve as a scaffold for additional trans-synaptic proteins 
(70,71). Perhaps if the pool of receptors and their interactors such as PSD-95 in 
the peripheral membrane reached sufficient density and complexity, that pool 
could recruit presynaptic branching and an opposed axonal terminal, thereby 
creating a shaft synapse. Together with our findings regarding the increased 
amounts and surface presentation of NMDA receptor subunits in the absence of 
Fbxo2, we propose that failure to clear NMDA subunits both from the ER and 
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upon activity-dependent endocytosis results in aberrant clustering in the 
peripheral membrane (Fig 26). 
The mechanisms regulating the formation and removal of excitatory shaft 
synapses are not well characterized. Excitatory shaft synapses are relatively 
uncommon under normal physiologic conditions (47), but their formation can be 
rapidly induced following LTP in the hippocampus (47,72). Shaft synapse 
numbers can also increase following experiential and behavioral modifications of 
awake, behaving animals (73-75). As shaft synapses are opposed to presynaptic 
terminals, it seems likely that postsynaptic rearrangement and clustering of 
proteins is able to induce the recruitment of presynaptic terminals. However, the 
formation of shaft connections is not necessarily an intermediate step toward the 
creation of spines extending from the shaft, as has been suggested elsewhere 
(47,76). Spine outgrowth precedes synaptic connectivity (77) and studies of post-
synaptically over-expressed EphB3 reveal an increase in shaft synapses with no 
effect on spinogenesis (78). 
The mechanisms by which shaft synapses are removed are also unclear. They 
can be rapidly removed following tetanic stimulation (47,73) or persist for hours 
(72).  The precise conditions that trigger the selective removal of shaft synapses 
are not known. Blockade of activity has been shown to cause the selective 
elimination of shaft, but not spinous, synapses; in contrast, epileptiform activity 
induces a reduction in spinous, but not shaft, synapses (79).   “Removal” itself 
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may be a misnomer; it has been proposed that as a part of maintaining 
potentiation, the synaptic surface architecture of rapidly produced shaft synapses 
is redistributed to strengthen and enlarge selected spinous synapses (47). 
Whether this relocation makes use of lateral mobility or the removal and 
reinsertion of receptors is not known, and why no such increase in spine head 
size is observed in Fbxo2 knockout mice remains uncertain. Because the loss of 
shaft synapses is governed by processes unknown to us, it is not currently 
possible to answer whether this still undefined process mediates the reduction in 
GluN1 levels observed in knockout animals following incubation in ACSF.  
Extensive remodeling of synaptic connections has been reported following 
preparation of acute slices (80). To bridge our morphological and 
electrophysiological findings, further studies will be required to address whether 
the additional amount of GluN1 lost during incubation after slice culture 
preparation represents a loss of shaft synapses in CA1.  
The rapid induction of shaft synapses following over-expression of the post-
synaptic protein EphB3 is marked by increased excitatory transmission in 
cultured neurons (78). It is conceivable that in vivo, an increase on the scale 
observed in Fbxo2 knockout mice would lead to epileptogenic activity, which 
could be fatal to animals. Therefore, the silencing of such synapses may be an 
essential, compensatory homeostatic response. It is possible that the localization 
of shaft synapses makes them more potent (81) and causes the loss of input 
selectivity, which could evoke a compensatory change in the length of dendritic 
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spines (82), as we observed (Fig 24). Alternatively, the difference in transmission 
through spines of different lengths may reflect multiple factors (83). Additional 
studies exploring the formation and turnover of shaft synapses will address their 
contribution to learning and memory.
FIGURE LEGENDS
Figure 14. Co-expression of Fbxo2 decreases levels of unassembled NMDA 
Receptor Subunits 
(a) Co-expression with Fbxo2 reduces GluN1 levels. HEK293 cells expressing 
GFP-GluN1 together with vector encoding Fbxo2 or empty vector (EV) were 
harvested 48 hours after transfection, and lysates were examined by western blot 
with antibodies recognizing GluN1, Fbxo2, or GAPDH. (b) GluN2A  and (c) 
GLuN2B levels are similarly decreased following co-expression with Fbxo2. 
Fbxo2 and GluN2A or GluN2B were co-expressed as in panel a, and subunit 
levels assessed by western blot with anti-GluN2A or  anti-GluN2B antibody. 
Results shown are representative of triplicate experiments. (d) Quantification of 
results from panels a-c. Error Bars = S.E. *, p<0.05; ** p<0.01; **** p<0.0001; 
(unpaired t test).
Figure 15. Increased levels of GluN1 and GluN2A, but not GluN2B, in Fbxo2 -/- 
brain.
The absence of Fbxo2 increases (a) GluN1 and (b) GLuN2A subunit levels, but 
not (c) GluN2B subunit levels, in whole brain. Subunit levels in brain lysates from 
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wild-type and Fbxo2 null mice were assessed by western blot, with 
representative immunoblots (upper panels) shown for three mice of each 
genotype at three months of age Subunit  levels were quantified (lower panels) 
and normalized at four ages, with an n of three animals per genotype at each 
age. (d) GluN2A  and (e) GluN2B associated with hippocampal membranes 
remain Endoglycosidase H sensitive.  GluN2A or GluN2B was 
immunoprecipitated from hippocampal membrane fractions of 6-month old wild-
type mice, then  incubated with Endo H, PNGase F or (as control) PBS alone. 
Deglycosylation of GluN2A or GluN2B was then assessed by western blot with 
anti-GluN2A or GluN2B antibody, respectively. The observed sensitivity to Endo 
H, indicating the presence of retained high mannose glycans on GluN2A and 
GluN2B, was not altered in Fbxo2 null mice. Error Bars = S.E. *, p<0.05 
(unpaired t-test).
Figure 16. Immunofluorescence confirms increased GluN1 and GluN2A levels in 
Fbxo2 -/- brain.
Confocal immunofluorescence microscopy in (a) cortex and (b) CA1 region of 
hippocampus shows increased levels of GluN1 (left column) and GluN2A (center 
column) in 6 month old Fbxo2 knockout mice (lower row) compared to wild-type 
mice (upper row). 
Figure 17. Elevated levels of PSD-95 and Vglut1 in Fbxo2 -/- brain.
(a) PSD-95 and Vglut1 immunofluorescence are increased in the CA1 region of 6 
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month old Fbxo2 null mice (lower row) versus wild type mice (upper row), while 
Spinophilin and VGAT levels are unchanged. (b) Quantification of 
immunofluorescence results from three mice per genotype. (unpaired t-test).  (c) 
GluR1 levels  in hippocampus of 6 month old wild-type and Fbxo2 null mice was 
assessed by western blot using an anti-GluR1 antibody (left panel).  
Quantification of immunoblots from three mice per genotype  (right panel) 
showed no change in GLuR1 levels. Error Bars = S.E. *, p<0.05 
Figure 18. NMDA receptor levels and cell surface localization are increased in 
cultured Fbxo2 -/- hippocampal neurons
(a) GluN1 and GluN2A levels are increased in cultured Fbxo2 null neurons, 
whereas GluN2B levels are decreased.  Cultured hippocampal neurons isolated 
from p3 wild type and Fbxo2 null mice, DIV 14, were lysed and NMDA receptor 
subunit levels assessed by western blot. Representative results from three 
dishes per genotype are shown (left panels) and  quantified (right panel). (b) 
Fbxo2 absence results in greater cell surface localization of GluN1. Intact 
neurons were treated with chymotrypsin for 15 minutes or left untreated, then 
lysed, and GluN1 levels were assessed by western blot.  Representative 
immunoblot results from a single experiment are shown (left panel) and results 
from triplicate experiments were quantified (right panel). (c) the amount of 
surface GluN1 remaining after 48 hour exposure to 50uM bicuculline, as detected 
by cell-surface ELISA assay, is reduced to approximately 50% of those in 
untreated controls for wild-type neurons, but for Fbxo2 knockout neurons, no 
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surface immunoreactivity is lost following treatment. Treated and untreated 
cultures were labeled with an antibody against the extracellular loop of GluN1, 
which was then labeled with Horse Radish Peroxidase(HRP)-conjugated 
secondary antibody.  HRP cleavage of Tetramethylbenzidine in triplicate cultures 
per genotype per treatment was then detected and quantified. Error Bars S.E. *, 
p<0.05, ** p<0.005*** p<0.001; **** p<0.0001 (unpaired t test).  
Figure 19. Greater GluN1 immunoreactivity colocalizes with the presynaptic 
marker VGlut1 in cultured hippocampal neurons
(a) GluN1 immunoreactivity in DIV 14 cultured hippocampal neurons was 
assessed by fluorescent confocal microscopy. Neurons were fixed, 
permeabilized, and immunostained for GluN1 (left column) and the synaptic 
marker Vglut1 (second column). GluN1 puncta (arrows) colocalize with Vglut1 
puncta (second and third columns, arrows). Two representative neurons per 
genotype are shown. (b) Consistent with western blot results, GluN2A 
immunoreactivity is increased in cultured hippocampal neurons (b) and GluN2B 
is decreased (c). Scale bar = 25um.
Figure 20. Enhanced Surface Localization of GluN1 and GluN2A in Hippocampi 
of Fbxo2 -/- mice
Acute hippocampal slices from six month old mice were incubated with 
oxygenated ACSF with or without biotin for 45 minutes, and processed to 
measure surface proteins (see Experimental Procedures). Surface levels of 
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GluN1 and GluN2A are nearly doubled in the absence of Fbxo2.  Total and 
surface fractions were examined by western blot for GluN1, GluN2A, GAPDH, or 
the transferrin receptor as a control glycoprotein known to have some surface 
expression.  Representative immunoblot results are shown from a single animal 
of each genotype (left panel).  Slices from three animals per genotype  were 
examined and the results quantified (right panel).  Error Bars = S.E. ** p<0.01 
(unpaired t test). 
Figure 21. The loss of Fbxo2 does not alter hippocampal synaptic transmission
(a) fEPSPs were measured in acute slices of hippocampi from wild-type and 
Fbxo2 knockout mice at the indicated stimulus intensities both in the presence 
and absence of CNQX (empty and filled circles, respectively) and quantified.  
Neither Ampa nor NMDA-mediated currents differed between genotype. Fiber 
volley amplitude (b) was similarly unchanged.   No difference was observed when 
fEPSPs were plotted against fiber volley amplitude (c). 
Figure 22. The loss of Fbxo2 does not alter hippocampal synaptic miniature 
synaptic currents or LTP induction
(a) Examples of AMPAR mEPSCs from acute hippocampal slices from litter mate 
wild-type and knockout mice. Cumulative fraction (b, left panel) and histogram 
distribution (insert) of mEPSC amplitude are unchanged in knockout mice. The 
amplitude average (b, right panel) is comparable between wild-type and 
littermate-matched knockout mice. Cumulative fraction (c, left panel) and 
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histogram distribution (insert) of mEPSC frequency is not significantly changed in 
the absence of Fbxo2. The frequency average (c, right panel) is comparable 
between wild-type and knockout mice. Cumulative fraction (d, left panel) and 
histogram distribution (insert) of mEPSC decay tau is not significantly changed in 
knockout mice. The decay tau average (d, right panel) is comparable between 
wild-type and knockout mice. P values of 2-tailed student t-test are shown in 
each subpanel. (e) LTP is not affected in Fbxo2 knockout mice. LTP was induced 
by a single tetanus (1 s/100 Hz; arrow in i.) in CA1 of acute hippocampal slices 
from Fbxo2 knockout and littermate-matched wild-type control mice.  Example 
fEPSPs recordings before (dashed lines) and 60 min after LTP induction (solid 
lines) from wild-type and knockout mice are shown.  (i) Averages of the complete 
time courses are shown from wild-type and knockout mice. LTP is comparable in 
hippocampal slices from wild-type and knockout mice.
Figure 23. GluN1 levels are equilibrated following lengthy incubation in ACSF.
(a) GluN1 levels are increased in hippocampi from six-month old Fbxo2 null mice 
when rapidly lysed following excision.  Following slicing and 5 hour incubation in 
ACSF in preparation for electrophysiology studies, GluN1 levels no longer differ 
between genotypes. (b) Immunoblot of slices lysed one hour after cutting still 
demonstrate elevated levels of GluN1 in Fbxo2 knockout hippocampi consistent 
with those seen following immediate lysis (left panel).  Western blot results from 
three mice per genotype per condition were quantified (right panel). Error Bars = 
S.E. *, p<0.05, ** p<0.01 (unpaired t test). 
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Figure 24. Dendritic Spine Density is not affected by the loss of Fbxo2
(a) Dendritic spines of CA1 pyramidal neurons from 6 month old mice were 
labeled with DiI and imaged by confocal laser microscopy, then reconstructed 
using Imaris software (see Experimental Procedures) as represented in an 
example of imaged spines (top panel) and their reconstruction (with dendrite 
reconstruction removed to aid visualization, lower panel) is shown.  Scale bar = 
5um. (b) Representative examples of wild-type and Fbxo2 null  dendrites are 
shown. Scale bar = 10um. (c) Quantification of dendritic spine density reveals no 
difference between genotypes (upper left panel). Spine length is decreased by 
22% in the absence of Fbxo2 (upper right panel).  Spine head diameter is 
increased by 5% (lower left panel) and spine neck diameter is decreased by 12% 
(lower right panel) in Fbxo2 knockout mice. Quantified data represent 
approximately 6,000 spines from 60 dendritic segments per genotype. Error Bars 
S.D. **** p<0.0001 (unpaired t test).  
Figure 25. Increased density of axo-dendritic shaft synapses in CA1 of Fbxo2 -/- 
mice 
Transmission Electron microscopy reveals increased dendritic shaft synapses in 
CA1 region of hippocampus from six month old Fbxo2 null mice. Representative 
images show synapses on dendritic shafts (false-colored green) at sites adjacent 
to spinous synapses (a and inset, b) and along peripheral membranes (c and e, 
with respective insets d and f). Synapses were identified by the presence of an 
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electron-dense postsynaptic structure (arrows, c, d, f) opposed to a presynaptic 
terminal with visible, round, synaptic vesicles (labeled V, panels b, d, and f.)  The 
increase in density of shaft synapses per animal was quantified (g) from 500um 
of dendritic length from 4 animals per genotype. Shaft synapses were also found 
less frequently in wild-type dendrites, as shown in (h) and inset (i).  Error Bars 
S.E. *, p<0.05 Scale bars = 500nm (a,c,e, h) and 250nm (b, d, f, i).
Figure 26. Proposed Model for the Altered Handling of NMDA receptors and 
Aberrant Formation of Axo-Dendritic Shaft Synapses in the Absence of Fbxo2
[1] Based on co-expression experiments with uncoupled receptor subunits and 
analysis of brain lysates, we propose that Fbxo2 may play a role in limiting the 
steady-state levels of newly-synthesized GluN1 and N2A in the ER. [2] As steady 
state levels increase, subunits complex together with scaffolding and 
transynaptic proteins and leave the ER to be trafficked to synapses.  [3] 
Homeostatic mechanisms limit the number of NMDA receptors at a given 
synapse, shuttling unused receptor complexes to and from reserve pools at non-
synaptic sites in the peripheral membrane.  [4] As NMDA receptors are 
endocytosed in response to activity or as part of their normal lifespan, the option 
to degrade these receptors is lost in the absence of Fbxo2, cauing all receptors 
to recycle back to the surface, keeping the reserve pool large. [5] Given sufficient 
density of receptor complexes - with associated scaffolds and trans-synaptic 
proteins - recruits pre-synaptic branching to create axo-dendritic shaft synapses.
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Figure 14. Co-expression of Fbxo2 decreases levels of unassembled NMDA 
Receptor Subunits
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Figure 15. Increased levels of GluN1 and GluN2A, but not GluN2B, in Fbxo2 -/- 
brain.
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Figure 16. Immunofluorescence confirms increased GluN1 and GluN2A levels in 
Fbxo2 -/- brain.
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Figure 17. Elevated levels of PSD-95 and Vglut1 in Fbxo2 -/- brain.
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Figure 18. NMDA receptor levels and cell surface localization are increased in 
cultured Fbxo2 -/- hippocampal neurons
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Figure 19. Greater GluN1 immunoreactivity colocalizes with the presynaptic 
marker VGlut1 in cultured hippocampal neurons
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Figure 20. Enhanced Surface Localization of GluN1 and GluN2A in Hippocampi 
of Fbxo2 -/- mice
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Figure 21. The loss of Fbxo2 does not alter hippocampal synaptic transmission
140
Figure 22. The loss of Fbxo2 does not alter hippocampal synaptic miniature 
synaptic currents or LTP induction
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Figure 23. GluN1 levels are equilibrated following lengthy incubation in ACSF.
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Figure 24. Dendritic Spine Density is not affected by the loss of Fbxo2
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Figure 25. Increased density of axo-dendritic shaft synapses in CA1 of Fbxo2 -/- 
mice
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Figure 26. Proposed Model for the Altered Handling of NMDA receptors and 
Aberrant Formation of Axo-Dendritic Shaft Synapses in the Absence of Fbxo2
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Chapter Four: Conclusions and Future Directions
In the preceding chapters I have explored the contributions of ubiquitin-mediated 
processes to neuronal health and function. In Chapter 1, I began by describing 
examples of the diverse, significant roles for ubiquitination in the most common 
neurodegenerative diseases.  In Chapter 2, I explored the dysregulation of 
Amyoid Precursor Protein levels, localization, and processing following the loss 
of a single protein in the Ubiquitin Proteasome System, the brain-enriched E3 
ligase substrate adaptor protein Fbxo2. In Chapter 3, I investigated the subunit-
selective regulation of NMDA receptors by Fbxo2, and the complex homeoplastic 
regulation of these receptors and associated synaptic structures at the cell 
surface in the absence of Fbxo2.  Here, I consider the broader implications of the 
work described in Chapters 2 and 3 on the need for further study of, and 
therapeutic intervention into, the problems associated with ubiquitination 
described in Chapter 1. I will focus my discussion on Alzheimer’s Disease (AD) 
because of the links I have established in the preceding chapters to Fbxo2.
 The question of potential clinical relevance underlies all of the work 
undertaken in our laboratory.  Several factors influence the potential for 
translating our discoveries into meaningful insights into human disease and the 
design of potential therapies.  
 The first of these factors is the interchange between human disease and 
animal models. A great deal of what we believe about the protein-mediated  
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mechanism of human disease stems from studies of animal models which 
seldom faithfully recapitulate the features of human disease. These models often 
employ the expression of human or humanized proteins in non-human systems 
at levels which greatly exceed the physiologic levels of similar murine proteins. 
The expression of these proteins can be driven through extra-chromosomal 
means, and in doing so greatly change the landscape of gene transcription for 
the protein of interest.  In the case of Fbxo2, our next logical step would be to ask 
whether the regulation of endogenous murine Amyloid Precursor Protein (APP) 
by Fbxo2 extends to mutant APP in AD mouse models.  However, there is some 
question as to whether overexpressed, mutant APP is processed in the same 
way as endogenous APP (201). Alternative processing of mutant APP could 
occur in a manner that is independent of the expression of Fbxo2, and, given the 
massive over-expression of mutant APP in AD mouse models, actually mask 
smaller changes in the handling of endogenous APP. This could result in no 
detectable difference in amyloid levels between AD mice and AD mice lacking 
Fbxo2 even if Fbxo2 does normally help regulate endogenous APP. Alternatively, 
Fbxo2 may facilitate the degradation of mutant and wild-type APP in vivo equally.  
The studies necessary to elucidate this point will require careful consideration of 
the appropriate AD mouse model, but could shed light on an important 
contribution to the processing of APP. 
 To address the need for model systems with greater fidelity to the 
biological problem, it would be of interest to suppress Fbxo2 expression in 
Induced Pluripotent Stem Cells (IPSCs) from AD patients and healthy adults of 
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various ages differentiated into neurons.  While neurons in a dish will never 
recreate the complex connectivity of an intact brain, the study of wild-type and 
mutant human APP expressed in human cells at endogenous levels would allow 
us to determine whether what we observed here in mice also holds true in human 
neurons, and whether it extends to mutant APP as well. 
 In designing experiments with animal models, further consideration must 
also be given to the question of whether the reduction of Fbxo2 levels reported in 
AD patient tissue (90) occur early in disease or only as a late-stage 
phenomenon. While no mutations associated with Fbxo2 have yet been reported 
for AD or any other neurodegenerative disease, the timing of any reduction in 
Fbxo2 levels could be critical in determining the impact such a change has.  In 
the studies by Gong et al., transient changes to Fbxo2 levels resulted in an 
observed effect on BACE1 (90).  In our studies, we were able to observe that 
same effect in a transient transfection model but not invivo, where the loss of 
Fbox2 was chronic.  Similarly, the greatest difference in APP levels between wild-
type and Fbxo2 knockout mice occurred at 3 months of age, at the time point 
when Fbxo2 expression is highest in the wild-type brain.  As the knockout 
animals aged, however, the observed increase in APP expression began to 
revert to levels matching those of wild-type mice, around 9 months of age. 
Intriguingly, the difference in GluN1 does not appear to normalize with aging, 
while the difference in GluN2A levels over time mirrors that of APP (Atkin, 
unpublished data). These findings suggest that additional, compensatory 
changes allow the brain to adapt to the loss of Fbxo2 and normalize APP 
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handling. Thus, if the impact of Fbxo2 knockout on the metabolism of APP and 
associated glycoproteins in the Amyloid Pathway is temporally restricted, the 
effect of reduced Fbxo2 levels on the pathogenic pathways of AD might well 
depend on when that decline in Fbxo2 first occurs. Access to patient brain tissue 
at several ages and degrees of disease severity would help greatly in clarifying 
this important point. Additionally, the creation of a conditional Fbxo2 knockout 
mouse could reveal the significance of reduced Fbxo2 levels beginning at 
different ages and, when crossed with AD model mice, different stages of amyloid 
plaque deposition. 
 Another important consideration in assessing the potential clinical 
significance of Fbxo2 modulation pertains to the proliferation of synapses. The 
loss of synapses is observed in numerous neurodegenerative diseases and is 
considered the best morphological correlate for cognitive decline. This loss of 
synapses seems like an obvious problem in which modulating Fbxo2 activity 
could prove beneficial, as our studies reveal a significant increase in synapses in 
vitro and in vivo in the absence of Fbxo2.  And yet our morphological examination 
of these structures suggests they are aberrantly localized, and our 
electrophysiological studies reveal that they do not participate in synaptic 
transmission or potentiation in a detectable manner.  We must consider, then, 
that even if we were able to reduce Fbxo2 levels in a disease context and 
increase the numbers of synaptic connections, it might fail to benefit to cognitive 
function. Restoring synapse number without attention to the localization and 
composition of those additional synapses may not improve cognition.  If the loss 
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of Fbxo2 increases the levels of one or more proteins necessary for the formation 
of synaptic connections, perhaps additional, combined interventions could 
redirect those additional synaptic building blocks to sites where neurons are 
optimally able to incorporate their function, such as spinous synapses.  The 
precise mechanisms leading to the loss of synapses in disease states have yet to 
be understood, but perhaps this decline could be balanced out by the combined 
efforts of knocking down Fbxo2 and increasing other mechanisms regulating 
synaptogenesis in order to achieve normal numbers of functional synapses and 
preserve cognitive functions. 
 Here, again, a conditional Fbxo2 knockout mouse could prove useful to 
assess the potential for staving off age-related synaptic loss.  The idea of 
creating an over-expression model of Fbxo2 also raises fascinating scientific 
questions about the intersection of protein quality control and synaptic plasticity 
systems.  In Fbxo2 knockout mice, the overabundance of NMDA receptors (and 
likely other synapse-related proteins) does not compromise the regulation of 
dendritic spine number or architecture and synaptic transmission.  The 
unchanged level of the AMPA receptor subunit GluR1 in knockout mice suggests 
a possible mechanism by which additional proteins may compensate for the 
effects of Fbxo2 loss.  Such a mechanism could include the removal of AMPA 
receptors in an effort to sustain the Mg2+ block on NMDA receptors, or an 
increase in activity-dependent kinases whose modification of NMDA receptor 
subunits results in diminished NMDA receptor function, Protein Kinase C has 
been shown to do (1). What remains to be seen is whether the converse is true: 
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could decreasing NMDA receptors by over-expressing Fbxo2 limit the formation 
of synapses if necessary minimum levels of substrate proteins aren’t met? Or 
could other as yet unknown mechanisms compensate by inactivating Fbxo2 or 
limiting its access to high-mannose glycans on substrate proteins?
 Finally, the potential unintended consequences of knocking down Fbxo2 
must be addressed when we consider the possibility of regulating Fbxo2 levels 
as a therapeutic intervention.  Fbxo2 is merely one component of the UPS, and 
functions by complexing with other components to facilitate ubiquitination.  
Diverse combinations of UPS agents are able to form into a wide array of multi-
subunit complexes that can allow for the recognition and handling of a large 
number of substrates (2). Fbxo2 has been shown to function with CHIP (3), but in 
our own unpublished work has also be found to interact with the RING-type E3 
ligase Trim3 (Atkin, unpublished data).  Trim3 is also involved in synaptic 
plasticity, facilitating the activity-dependent degradation of the post-synaptic 
scaffolding protein GKAP (4). Additional studies using mass spectroscopy of 
brain samples from wild-type and Fbxo2 knockout mice revealed interaction 
between Fbxo2 and AP2A2, which is involved in the trafficking of surface proteins 
including synaptic receptors, and with the calcium-activated kinase CAMKII, an 
important regulator of long-term potentiation (Atkin, unpublished data). Fbxo2 
was originally identified for its recognition of high-mannose glycans on potential 
substrates (5). Nearly half of all proteins are glycosylated as part of their 
synthesis and maturation (6). Thus, the list of proteins eligible for recognition and 
handling by Fbxo2 is potentially enormous. However, because our studies 
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revealed subunit-selective regulation of NMDA receptors in vivo by Fbxo2, the 
presence of high-mannose glycans may be necessary but not sufficient for 
substrate recognition. Taken together, these findings suggest that many proteins 
important for the health and function of neurons could be regulated by Fbxo2, but 
that further investigation will be needed to move possible substrates from the list 
of eligible candidates to proven substrates. These further investigations will also 
need to consider that Fbxo2 recognition of substrates may be restricted to 
specific activity-dependent states in neurons.  Without a better understanding of 
the scope of proteins regulated by Fbxo2, altering its expression cannot be 
embraced as a potential therapy for Alzheimer’s Disease or cognitive decline.  
Examining the large-scale proteomic changes following Fbxo2 knockout in 
cultured neurons or brain is certainly feasible. And although such a study would 
not necessarily provide an exhaustive description of every protein whose level 
changes in the absence of Fbxo2, it would shed informative light on the broad 
scope of major changes.  From there, a more refined strategy to target specific 
Fbxo2 substrates could be designed. 
 The etiology of Alzheimer’s Disease appears extraordinarily complex. And 
while considerable time, effort, and money have been spent attempting to identify 
the individual events leading to disease, no effective treatments have resulted. 
The selective inhibition of secretase enzymes and the targeted elimination of 
Amyloid-Beta have not yet improved disease outcomes in human clinical trials. It 
may be that a less discriminate, less discrete intervention is called for.  UPS 
agents like CHIP and Fbxo2 have the potential to influence a wide array of 
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substrate proteins and cellular processes. Modifying these agents might yield 
extensive, complex, and difficult to unravel proteomic changes, but the chance to 
improve neuronal health and cognitive function underscores that these are 
crucial areas of further investigation. 
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